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SUMMARY 
The term glycation is used to describe non-enzymatic sequence of reactions in which 
the nucleophillic groups of,proteins, nucieic acids and lipids react with reducing 
sugars and result in the formation of complex adducts including advanced glycation 
endproducts (AGEs). Glycation is also accompanied by the formation of reactive 
oxygen species (ROS) and causes oxidation, degradation and other alterations in 
biomolecules including inactivation of enzymes, both in vitro and in vivo. Glycation 
is a slow process but has been imphcated in a variety of disorders including diabetes, 
atherosclerosis and various micropathies. An attempt has been made in this thesis to 
evaluate simple and reliable strategies for the assay of protein glycation and screening 
of various inhibitors of protein glycation. 
Glycated human serum albumin (HSA) is known to be involved in pathogenesis of 
several diabetic complications. The alterations resulting from incubation of HSA with 
various sugars was studied. HSA was incubated for upto 8 days with glucose, fructose 
or ribose at 37°C under aerobic conditions. The extent of glycation of HSA as well as 
accompanying structural alterations were studied using SDS-PAGE, fluorescence, 
hyperchromicity, circular dichroism (CD) and colorimetric techniques. There was a 
consistent decrease in tryptophan fluorescence and increase in fluorescence as 
ascribed to the formation of AGEs. The structural alterations shown by CD spectra 
were suggestive of increase in the beta structure and random coil at the expense of 
alpha helix. HSA incubated with the sugars revealed an increase in carbonyl content 
with increase in time of incubation. The alterations produced by fructose and ribose, 
measured by most parameters were more pronounced than those caused by glucose 
with the exception of ketoamine and periodate assays that indicated low reactivity of 
fructose. The protective role of various compounds, drugs and flavonoids against the 
sugar-induced alterations were also studied. Among the flavonoids, rutin and 
1 
quercetin were potent inhibitors of fructose-induced alterations in HSA, while 
naringin and myrecetin were moderately protective. 
Incubation with various reducing sugars at 37° C also results in remarkable 
inactivation of bovine pancreatic RNase A and among those investigated, ribose was 
most reactive followed by fructose and glucose. The loss of RNase A activity was 
accompanied by parallel conformational and other changes in the enzyme as revealed 
by increase in new fluorescence, quenching of intrinsic fluorescence, 
hyperchromicity and loss in tertiary structure. SDS-PAGE of RNase A incubated with 
the sugars showed cross linking and/or fragmentation. Protective role of various 
compoimds and some flavonoids against glycation induced enzyme inactivation and 
other changes were also studied. As observed earlier with HSA the order of protection 
provided by flavonoids was- rutin > quercetin> naringin> myricetin > catechin. 
Taking into consideration the remarkable thermostablity of RNase A and high 
reactivity of ribose as well as sensitivity of RNase A activity to glycation, a novel assay 
procedure for the screening of inhibitors of glycation was developed. Incubation of 
RNase A with ribose at 60 "C resulted in rapid inactivation of the enzyme in two days 
with a parallel decrease in tyrosine fluorescence, enhancement in new fluorescence 
and hyperchromicity in the UV-region. No such alterations were observed when the 
incubation was carried out in absence of the sugar. Several drugs, flavonoids and 
other compounds that are known to act as inhibitors of glycation reactions also 
restricted the ribose-induced inactivation of RNase A. RNase A immobilized on 
CNBr-activated Sepharose was more stable but equally sensitive to incubation with 
ribose. The immobilized RNase A was superior for the screening of the inhibitors of 
glycation from natural sources which contain substances that interfered with the 
assay of enzyme. Immobilized RNase A could be readily removed from the reaction 
mixture, washed and the activity determined in the absence of the interfering 
substances. The immobilized preparation was also suitable for the assay of post 
Amadori inhibitors of glycation since it facilitated the ready separation of the enzyme 
from the reaction mixture after initial reaction with sugars. 
An earlier study from this laboratory has shown that anti Cu, Zn-SOD antibodies 
protect the enzyme against inactivation induced by reducing sugars and dicarbonyls. 
RNase A bound to Sepharose supports precoupled with antiRNase A antibodies raised 
in rabbits were similarly more resistant to inactivation induced by some reducing 
sugars as compared to the soluble enzyme or that bound non-covalently to CM 
cellulose. The spectral properties (hyperchromicity, quenching of tyrosine 
fluorescence and new fluorescence) of the RNase A exposed to the sugars in the 
immobilized state showed that binding on the antibody support provides remarkable 
protection against the glycation-induced alterations, CM cellulose support was only 
moderately protective against sugar induced alterations. 
STUDIES ON PROTEIN GLYCATION 
THESIS 
SUBMITTED FOR THE AWARD OF THE DEGREE OF 
Boctor of ^I)Uos[opI)p 
tN 
BIOCHEMISTRY 
BY 
SHAMILA FATIMA 
DEPARTMENT OF BIOCHEMISTRY 
FACULTY OF LIFE SCIENCES 
ALIGARH M U S L I M UNIVERSITY 
AL IGARH ( INDIA) 
2008 
S^ 
a A'ad 
T7069 

University Exchange Nos. 
0571-2700920,2700916 
Ext, (INT)Office-3720 
Chairman's Chamber - 3721 
Ext. (0571)2700741 
Fax. No. (0571)2706002 
D E P A R T M E N T O F B I O C H E M I S T R Y 
FACULTY OF LIFE SCIENCES 
ALIGARH MUSLIM UNIVERSITY 
ALIGARH-202002 (INDIA) 
Ref. No.. Dated. 
Certificate 
This is to certify that the work embodied in the thesis entitled ^''Studies on 
protein glycation" has been carried out by Ms. Shamila Fatima under my 
supervision. It is original in nature and is suitable for the award of Ph.D. degree in 
Biochemistry of the Aligarh Muslim University, Aligarh. 
011^-^ l<-M-A^  
M. Saleemuddin \ " > | ^ | o ^ 
(Supervisor) 
Jic^owled^ement 
In the name ofJlCCafi the cfierisher and tfie sustainer of the worCds who gifted 
man xvith the e^raordinary power of thin^ng and who provided me enough zeaCfor 
the completion of this wor^ 
Jit the very unset, I wish to ey^ress my deep sense of gratitude to (Professor M. 
SaCeemuddin for his invaCuaSCe guidatice, moraC support, prudent suggestions, ^en 
interest and incessant encouragement during the entire course of this study. I have no 
worcfs to than^ him for aCC his favours, very understanding nature, highty usefuf 
discussions and each and every heCp. 
I am sincereCy gratefuC to (Prof S.M TCadi, Chairman, (Department of 
(Biochemistry for providing me att the research facilities required to pursue my worh^ 
unrestrictedCy. 
Speciat than^ are due to aCC my teachers (Prof MasoodAhmad, (Prof Ji.K% 
nCusufi, (Prof (BiCqees (Bano, Prof. fNaheed (Bano, (Prof Qayyum Hussain, (Dr (Riaz 
Mahmood, (Dr Imrana S^aseem, <Dr Mohd TaBish, Qr Tahim ^HaCim %han, (Dr 'Farha 
%hanfor helping me get my feet wet in the stream ofsuSjects. 
Profuse than^ are due to (Dr Tarha, (DrJLahgeena and(DrSheeSa who too^time 
from their Susy schedule to help me in my hour of need 
Council for Scientific and Industrial (Research is gratefully ac^owledged for 
proinding the necessary financial assistance. 
I also than^<Dr M Owais, (Dr (Rizwan J{ %han, (Dr Jisadullah 'Khan and (Dr 
Kina 'Younus for their support, guidance and help I received from them. I have no 
words to than^Mr Faisal for his computer facility. 
The ^ndhelp extended 6y Manzar Shai, Surinder 6hai, 9ioor 6hai, 'Wasim Shai 
and Qadir Shai is ac^nowlegedwith appreciation, 
I was fortunate enough to have (Dr Pawan ^upta, (DrHina Jamil, (Drjlrshi 
94.alih^ (DrSamina, (Dr JimjadJlH Xhan, (DrJLrivarasu as my seniors. I owe them a lot 
for their amicaSk help and guidance. 
fUBSlS 
Words of appreciation and tHan^ are due to my SatcRmates Asfer, Irfana, 
'Eram and YasHa for tfieir constant encouragement, positive criticism and suppori. 
Than^ are aCso due to my very nice junior coCCeagues Jlyesfia, Sadia, Shubha, J[iman, 
Mehreen, TosdiBa, !Nisfitfia, SaSi^, Sdams, Sarmad, SHeeSa, Sara, (Badar, 'Wasim, 
Vzma, Tafiad, Sdafinawaz, AaCiyaJltif ZoheS, ^^fisana, Sfia^ef, Ifte^r, Sandesh, 
Ashraf 9{ida, (BiCaC, Humaira, TaisaC, (Rjaz and Taqi for creating Civefy wor^ng 
atmosphere and tfieir cooperation, 
I owe a Cot to my friends SaSa, !Nidia, (PaCCavi and'Esfiafor their •warmth and 
pleasant companionship afthough !Nb words can adequateCy convey my than^ to 
<Ru6a6 who remained Besides me everytime I needed her. I find myseCf shori of words in 
offering my profound than^ to wards (DeeSa for aCf her cooperation and creating 
friendly wor^ng atmosphere. 
'With ate the sincerity I convey my gratitude to wards my parents for 
stimulating interest during my research endeavor Other memScrs of the famiCy atso 
deserve h^nd appreciation for their support. TinaCCy I aver my hearifeft than^ to my 
husBand Jtammad for his exquisite Benedictions, unflinching suppori, warmth and 
affection that is inspiring me to achieve the pinnacle of success in the academic world. 
A very special than^ to Jisfa for adding colors to my life and Bearing with the failures 
in commitment on my pari. 
Last But not the least I wish to offer my than^ to all whose names couhfnot Be 
included But unlT Be fondly rememBered. 
(ShamiCcL Tatima) 
Contents 
Abstract 
Abbreviations 
List of figures 
1.0 Introduction 
1.1. Protein glycation 
1.1.1 Chemistry of glycation 
1.1.2. Advanced glycation end products (AGEs) and their receptors 
1.2. Glycation of proteins with various sugars 
1.2.1. Glycation by fructose 
1.2.2. Glycation by ribose 
1.3. Glycation of various biomolecules 
1.3.1 Glycation of HSA 
1.3.2 Glycation of various enzymes 
1.3.2.1 Glycation ofRNase A 
1.4 Protein oxidation in diabetes 
1.5 Pathogenecity of glycation and AGEs 
1.6 Assays of glycation 
1.7. Prevention of glycation 
1.7.1. Natural defense 
1.7.2. Synthetic and natural inhibitors 
1.8. Objectives 
2.0 Materials 
3.0. Methods 
3.1. Glycation reactions 
3.1.1. In vitro glycation with various sugars 
3.1.2. In vitro glycation of HSA and RNase A with fructose along with 
various compounds/ drugs 
3.1.3. In vitro glycation of HSA and RNase A with fructose along with 
vario us flavono ids 
3.1.4. Incubation of soluble and immobilized RNase A with sugars 
3.1.5. Glycation ofRNase A at 60 "C 
3.2. Spectrophotometric analysis 
Page No. 
i 
iv 
V 
1 
1 
2 
6 
8 
8 
11 
12 
13 
16 
18 
20 
21 
23 
28 
28 
28 
35 
37 
38 
38 
38 
38 
39 
39 
39 
40 
^ ^ t i ^ ^ 
3.2.1 Determination of protein concentration 40 
3.2.2 Determination of protein bound carbonyl groups 40 
3.2.3. Borohydrideperiodate assay 41 
3.2.4 Determination ofketoamine groups in glycatedHSA 41 
3.2.5. AssayofRNaseA 42 
3.2.5.1 Effect of temperature 42 
3.2.5.2 Effect of pH 42 
3.3. Spectral Analysis 43 
3.3.1. UV absorption spectroscopy 43 
3.3.2. Flourescence spectroscopy 43 
3.3.3 Circular dichroism 43 
3.4 Immunological methods 44 
3.4.1 Immunization of rabbits 44 
3.4.2 Ouchterlor^ double diffusion 44 
3.4.3 Direct binding enzyme linked immunosorbant assay (ELISA) 44 
3.4.4 Isolation and purification of IgG 45 
3.5 Immobilization techniques 46 
3.5.1 Immobilization of antiRNase on CNBr activatedSepharose 46 
3.5.2 Immobilization ofRNase on CNBr activated Sepharose 47 
3.5.3 Immobilization ofRNase on CM-Cellulose 47 
3.5.4 Effectiveness factor 47 
3.6. Slab gel electrophoresis 48 
3.7.1. Polyacrylamide gel electrophoresis 48 
3.7.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 48 
3.8. Staining procedures 49 
3.8.1. Coomassie brilliant blue staining 49 
3.8.2. Silvernitrate staining 49 
4.0. Results 50 
4.1. Studies on glycation of HSA 50 
4.1.1 Effect of incubation with reducing sugars on the properties of 
HSA 50 
^.\.\.\SDS-PAGE 50 
4.1.1.2 Protein bound carbonyl groups 52 
4.1.1.3 Colorimetric determination ofglycation 52 
4.1.1.4 Spectral properties of HSA 55 
4.1.1.5 Effect of various compounds on glycation with fructose 55 
4.1.1.6 Effect ofsomeflavonoids on glycation with fructose 60 
4.2. Studies of RNase A 66 
4.2.1. Effectof reducing sugars on RNase A 66 
4.2.2. Effectof incubation with sugars on spectral properties of RNase A 66 
4.2.3. Effect of various compounds on the fructose induced alterations in 
RNase A 69 
4.2.4. Effect offlavonoids on the fructose induced alterations in RNase A 74 
43. Evaluation of RNase based assay for glycation 74 
4.3.1. Stability studies of immobilized RNase A 74 
4.3.1.1 Effect of temperature 74 
4.3A.I Effect ofpH 78 
4.3.2. Effect of incubation with sugars on RNase A activity 78 
4.3.3. Effect of incubation with sugars at 60 °C in the spectral properties 
of RNase A 81 
4.3.4. SDS-PAGE of RNase incubated with sugars 81 
4.3.5. Effect of some glycation inhibitors 85 
4.3.5.1 Effect of chemical compounds 85 
4.3.5.2 Effect of some plant extracts 87 
43.5.3 Effectof some flavonoids 87 
4.4 Use of immobilized RNase A for the study on glycation 90 
4.4.1 Immunization of rabbits and purification ofIgG 90 
4.4.2 Immobilization of RNase A on immunoaffinity and CM cellulose 
supports 
6.0 References 
90 
4.4.3 Effect of various sugars on soluble and immobilized RNase A 
preparation 90 
4.4.4 SDS-PAGE of RNase A exposed to the sugar in soluble and „ , 
immobilized state 
4.4.5 Effect of immobilization on sugar induced alterations in the 
conformation of RNase A "" 
5.0 Discussion JQJ 
113 
List of Publications and workshops attended ][35 
^ ^ ,-i i ' j = - 'k-
If 
~i/ 
ABSTRACT 
The term glycation is used to describe non-enzymatic sequence of reactions in 
which the nucleophilUc groups of proteins, nucleic acids and Upids react with 
reducing sugars and result in the formation of complex adducts including 
advanced glycation endproducts (AGEs). Glycation is also accompanied by the 
formation of reactive oxygen species (ROS) and causes oxidation, degradation and 
other alterations in biomoleoiles including inactivation of enzymes, both in vitro 
and in vivo. Glycation is a slow process but has been implicated in a variety of 
disorders including diabetes, atherosclerosis and various micropathies. An attempt 
has been made in this thesis to evaluate simple and reliable strategies for the assay 
of protein glycation and screening of various inhibitors of protein glycation. 
Glycated htraian serum albimun (HSA) is known to be involved in pathogenesis of 
several diabetic compUcations. The alterations resulting from incubation of HSA 
with various sugars was studied. HSA was incubated for upto 8 days with glucose, 
fructose or ribose at 37°C imder aerobic conditions. The extent of glycation of HSA 
as well as accompanying structural alterations were studied using SDS-PAGE, 
fluorescence, hyperchromicity, circular dichroism (CD) and colorimetric 
techniques. There was a consistent decrease in tryptophan fluorescence and 
increase in fluorescence as ascribed to the formation of AGEs. The structural 
alterations shown by CD spectra were suggestive of increase in the beta structure 
and random coil at the expense of alpha helix. HSA incubated with the sugars 
revealed an increase in carbonyl content with increase in time of incubation. The 
alterations produced by fructose and ribose, measured by most parameters were 
more pronounced than those caused by glucose with the exception of ketoamine 
and periodate assays that indicated low reactivity of fructose. The protective role 
of variovis compounds, drugs and flavonoids against the sugar-induced alterations 
were also studied. Among the flavonoids, rutin and quercetin were potent 
inhibitors of fructose-induced alterations in HSA, while naringin and myricetin 
were moderately protective. 
Incubation with various reducing sugars at 37° C also resvdts in remarkable 
inactivation of bovine pancreatic RNase A and among those investigated, ribose 
was most reactive followed by fructose and glucose. The loss of RNase A activity 
was accompanied by parallel conformational and other changes in the enzyme as 
revealed by increase in new fluorescence, quenching of intrinsic fluorescence, 
hyperchromicity and loss in tertiary structure. SDS-PAGE of RNase A incubated 
with the sugars showed cross linking and/or fragmentation. Protective role of 
various compovmds and some flavonoids against glycation induced enzyme 
inactivation and other changes were also studied. As observed earUer with HSA 
the order of protection provided by flavonoids was- rutin > quercetin> naringin> 
myricetin > catechin. 
Taking into consideration the remarkable thermostablity of RNase A and high 
reactivity of ribose as well as sensitivity of RNase A activity to glycation, a novel 
assay procedure for the screening of inhibitors of glycation was developed. 
Incubation of RNase A with ribose at 60 "C restdted in rapid inactivation of the 
enzyme in two days with a parallel decrease in tyrosine fluorescence, 
enhancement in new fluorescence and hyperchromicity in the UV-region. No 
such alterations were observed when the incubation was carried out in absence of 
the sugar. Several drugs, flavonoids and other compounds that are known to act as 
inhibitors of glycation reactions also restricted the ribose-induced inactivation of 
RNase A. RNase A immobilized on CNBr-activated Sepharose was more stable but 
equally sensitive to incubation with ribose. The immobilized RNase A was 
superior for the screening of the inhibitors of glycation from natural sources 
which contain substances that interfered with the assay of enzyme. Immobilized 
RNase A could be readily removed from the reaction mixtvure, washed and the 
activity determined in the absence of the interfering substances. The immobilized 
preparation was also suitable for the assay of post Amadori inhibitors of glycation 
since it facilitated the ready separation of the enzyme from the reaction mixture 
after initial reaction with sugars. 
An earlier study from this laboratory has shown that anti Cu, Zn-SOD antibodies 
protect the enzyme against inactivation induced by reducing sugars and 
dicarbonyls. RNase A bound to Sepharose supports precoupled with antiRNase A 
antibodies raised in rabbits were similarly more resistant to inactivation induced 
by some reducing sugars as compared to the soluble enzyme or that bound non-
covalentiy to CM cellulose. The spectral properties (hyperchromicity, quenching 
of tyrosine fluorescence and new fluorescence) of the RNase A exposed to the 
sugars in the immobilized state showed that binding on the antibody support 
provides remarkable protection against the glycation-induced alterations, CM 
cellulose support was only moderately protective against sugar induced alterations. 
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1.0 INTRODUCTION 
1.1 Protein glycation 
Glycation is an omnipotent, non-enzymatic process, occurring slowly but 
continuously in cells of all living organisms. This process involves chemical 
binding of sugar to amino groups of proteins followed by a series of chemical 
transformations (Singh et al., 2001). The nonenzymatic reaction of the amino 
groups of amino acids, peptides and proteins with reducing sugars, resulting in the 
formation of complex brown pigments and protein-protein crosslink, was first 
studied by L.C. Maillard in the early 1900s (Maillard and Gautier, 1912). The 
reactions therefore came to be known as the Maillard reactions. Food chemists 
however soon recognized the practical importance of the Maillard reaction in 
explaining the brown color formation and loss of protein quaUty in cooked and 
stored foods. Realization of the importance of Maillard reactions in vivo began in 
the mid-1970s with studies on hemoglobin Aic (HbAic), naturally occurring minor 
human hemoglobin that is elevated in diabetics (Bookchin and Gallop, 1968). 
HbAic was known to be the post-translational adduct of glucose, linked 
nonenzymatically to the N-terminal valine amino group of the p chain of 
hemoglobin in humans (Rahbar et al., 1969) and in animals (Koenig and Cerami, 
1975). Fliickigar and Winterhalter (1976) induced the formation of HbAic in vitro 
by incubating hemoglobin vvdth glucose. Later on, the significance of the complex, 
late stage Maillard processes was recognized as mediators of several complications 
in diabetes (Bimn etal., 1978) and aging (Monnier and Cerami, 1981). 
Proteins bearing Amadori products have come to be referred to as glycated 
proteins (distinguishing them from enzymatically glycosylated proteins) and the 
process of Amadori product formation is termed glycation. The complex pigments 
and cross-links formed from glycated protein during the in vivo Maillard reaction 
are described as advanced glycation end-products, or AGEs (Bucala et al, 1992). 
SIniro(kicti<m 
Wolffenbuttel et al. (1996) suggested that modification of hemoglobin by 
advanced glycosylation end products (Hb-AGEs) would be a better index for long 
term glycemia in diabetic patients. While glycation can be detected in physiologic 
conditions like aging, the reactions are considerably faster and more intensive in 
the pathophysiologic conditions Uke the uncontrolled diabetes meUitus associated 
with persistently elevated blood glucose concentration. 
Complex defence mechanisms restrict the glycation reaction in vivo, but small 
quantities of adducts of the proteins, nucleotides and basic phosphoUpids do ocaur 
under physiological states (Thomalley, 2003). The protection apparently goes 
astray in several disorders or when challenged with excess of reactive sugars over a 
prolonged duration. In addition to the multiple pathologies mediated by the in 
vivo generated AGEs, exogenous sources such as diet and smoking may also add 
significantly to the damage caused by those generated in the body (Kochinsky et 
al.. 1997). 
1.1.1. Chemistry of glycation 
Glycation involves a complex series of parallel and sequential reactions between 
reducing sugars and nucleophihc groups of proteins and other molecules leading to 
the formation of a variety of adducts, some of which are fluorescent and/or 
colored ( Cerami and Uliich, 2001). While the impact of glycation is coimtered in 
cells by high tvimover and short half-life of many cellular proteins, long Uved 
proteins accumulate glycation adducts with age (Sell et al., 1996). Although all 
these adducts are removed by degradation of the glycated protein, removal of 
extracellular protein adducts requires specific recognition receptors, 
intemahzation and proteolytic processing (Horiuchi et al, 1996; Gugliucci and 
Allard, 1996). 
Glycation can be subdivided into three main stages: early, intermediate, and late. 
In the early stage, glucose or other reducing sugars react with nucleophihc groups 
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like amino groups of proteins, nucleic acids and lipids to form unstable aldimine 
compovmds (Schiff bases). Through rearrangement, the Schiff base gives rise to the 
stable ketoamine (Amadori product). The rate of non-enzymatic reaction in vivo 
depends on the concentration of the sugar, reactivity of the free amino groups of 
the biomolecvdes and also on the half-life of the biomolecules. Under in vivo 
conditions, the Amadori products reach equiUbrium after approximately 15-20 
days and accumulate both on short-lived and long-Uved proteins (Thornalley, 
1996). The Amadori rearrangement of lysine-glucose Schiff base is thought to be 
faciUtated if a histadine side chain or another lysine group is present within about 
5A from the amino group on which the Schiff base has formed (Acosta et al., 
2000). In the intermediate stage the Amadori product is degraded into a variety of 
carbonyl compounds, such as glyoxal, methylglyoxal (MG) and deoxyglucosones 
which in turn act as propagators of the reaction (Thornalley et al., 1999; Glomb 
and Monnier, 1995). In the late stage, the propagators further react with other free 
amino groups and through irreversible oxidation, dehydration and cycUzation 
reactions form yellow-brown, heterogeneous AGEs (Fig.l). 
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Fig. 1. Schematic representation of formation of AGEs (Lin, 2006) 
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Several AGEs exhibit characteristic fluorescence and have reactive groups that 
may cross-Unk proteins, form insoluble aggregates and cause serious disturbance in 
their physiological functions (Ahmed etal., 2005). 
In recent years, it has become increasingly clear that dicarbonyl compounds are 
the key intermediates in the formation of AGEs. The Amadori product can break 
down via its enol form to reactive, free dicarbonyl glyoxal compoimds such as 3-
DG, MG, and glyoxal (Thornalley et al., 1999). These dicarbonyl compoimds are 
even more reactive towards amino groups of proteins than the parent sugars and 
rapidly lead to the formation of crosslinks and AGEs (Fig. 2). 
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Fig. 2. Schematic presentation of Maillard reaction pathway (Booth etal., 1997) 
SJniroJuction 
The increased levels of MG in diabetics and the identification of a number of 
AGEs that are derived from MG, make a strong case for the importance of this 
reactive a-oxoaldehyde in the development of diabetic complications (Boiirajjaj et 
al, 2003; Beisswenger et al., 2005). Increased MG formation is the consequence of 
increased availability of MG precursors such as plasma glucose, consumption of 
ethanol, threonine or accumvdation of fat (Wu, 2005). Overconsvunption of food 
containing carbohydrates and fat with high levels of ethanol provide precursors 
for MG generation and eventually cause an overproduction of MG in vivo (Wu, 
2006). MG initially reversibly reacts with arginine, lysine, or cysteine residues of 
proteins, and the subsequently irreversible reaction produces AGEs. MG is 
believed to be the most important source of AGEs (Shinohara et al., 1996; Bourajjaj 
era/., 2003). 
Glyoxal, another reactive a-oxoaldehyde and a physiologic metabolite, is formed 
by the oxidative degradation of glucose, lipid peroxidation, ascorbate autoxidation 
and degradation of glycated proteins (Wells-Knecht et al., 1995; Mlakar et al., 
1996; Schwarzenbolz et al., 2008). It can modify the side chains of various amino 
acids in proteins to give several glycation end products (Lederer and Klaiber, 1999; 
Brock et al., 2003; Thomalley, 2002). Furthermore, glyoxal also reacts with free 
thiol groups on amino acids, peptides and proteins to form thiol- aldehyde adduct 
(Zeng and Davies, 2005). 
Increased levels of MG/ glyoxal have also been reported in the blood from diabetic 
patients and in lens of streptozotosin-induced diabetic rats (Phillips, 1993; 
Mcllellan, 1994; LapoUa et al., 2003). Accvunulation of glyoxal, MG and other 
oxoaldehyde in cells lead to the modification of proteins that may lead to protein 
degradation, enzyme inhibition and a cytokine-mediated immune response (Vaca 
etal., 1994; Papuolis et al, 1995; Brinkmann et al, 1998; Westwood et al, 1997). 
Since a-oxoaldehydes are more reactive than glucose in glycation reactions, these 
intermediates potentiate the rate of protein glycation. Because the formation of a-
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oxoaldehydes can also occur due to fragmentation of Schiff base (Namiki 
pathway) as shown in Fig. 2, AGE may be formed without the delay required for 
the fructosamine formation via the Amadori rearrangement (Thomalley et al., 
1999). 
1.1.2. Advanced glycation end products (AGEs) and their receptors 
AGEs are the class of complex compounds formed as end products of glycation 
reaction (Wautier and Guillausseau, 2001). A nvraiber of AGEs are formed in vitro 
xmder conditions simidating the physiological state and some of these have also 
been isolated from himian tissues affected by disorders like diabetes. Most of the 
AGE intermediates are highly imstable and reactive, some of which are difficult to 
analyze. The term melanoidins initially proposed by Maillard is presimiably 
related with brown colour of the AGEs. Along with brown color, fluorescence is 
one of the quaUtative properties used to characterize the AGE formation. The first 
fluorescent AGE crosslink pentosidine was first isolated and identified from dura 
mater collagen (Sell etal., 1991). 
Pentosidine and CML are produced by the oxidation reaction at the advanced 
stage while pyralline is produced by non oxidative reaction from a-oxoaldehydes 
such as 3DG (Frye etal., 1998) Other important AGEs include hydroimidazolones 
derived from deoxyglucosone, Ng-carboxymethyl lysine, Ne-(l-carboxyethyl)-
lysine, pyrraline, several bis (lysyl) imidazoUvmi derivatives, pentosidine, 
argpyrimidine and arginine derived N5-(4-carboxy-4, 6-dimethyl-5,6dihydroxy-
l,4,5,6-tetrahydropyrimidine-2-yl)-ornithine (Ahmad et al, 2002; Kilhovd et al, 
2003). Based on the chemical structvure, three types of AGE may be distinguished: 
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A number of AGE receptors (RAGE) have been identified in macrophages, 
endothelial and several other types of cells (Skolnik et al., 1991). Phagocytic cells 
expressing RAGE internalize and digest AGE modified proteins and therefore 
these receptors are implicated in protein turnover, tissue remodeling and 
inflammation (Schmidt et al, 2001; Vlassara, 2001). Interaction of AGE with its 
RAGE generates intraceUvdar oxidative stress resulting in the activation of the 
transcription factor "HY-kappa B and subsequent gene expression which is relevant 
in diabetic complications (Zill et al, 2001). Cirailating AGEs are modified by 
various enzymes to highly reactive glycotoxins that enters blood circulation where 
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they generate new AGEs by reacting with plasma or tissue components. At this 
stage glycation accelerates the progress of deterioration Qakus, 2000) 
1.2. Glycatioii of proteins with various sugars 
Majority of the innimierable studies carried out on glycation reactions as discussed 
earlier focused on those mediated by glucose (glucation), since glucose is the most 
abundant sugar in blood and tissues. It is now well recognized that glucose and the 
level of the sugar is elevated remarkably in diabetes. Other reducing sugars have 
also been shown to cause glycation. These include galactose (Urbanowsi et al., 
1982), mannose and fucose (Zaman et al, 1981), glucose-6-phosphate (Hanney et 
al., 2003), ribose (Khahfah et al., 1996], glyceraldehydes (Acharya et al., 1992), 
sialic acid (McKinney et al., 2002), dihydroxyacetone (Peterson et al., 2004) and 
lactose (Scaloni et al., 2002). The extent of modification taking place in vivo have 
been minimal (1±2 mol of glycating agent attached per mol of protein) to high 
(30±40 mol per mol of protein) (Westwood and Thomalley, 1995; Thomalley et 
al., 2000). Excellent reviews are available on various aspects of glycation reactions, 
mainly by glucose (Ulrich and Cerami, 2001; Stitt, 2003). A more recent review on 
the fructose mediated glycation has also appeared (Schalkwijk etal, 2004). 
1.2.1. Glycation by fructose 
Recent years have witnessed a remarkable interest the in vivo and in vitro 
glycation reactions mediated by fructose (fructation) for a variety of reasons. 
Fructose, also described as the fruit sugar, is a ketohexose and the sweetest among 
the naturally occurring sugars. A recent study has shown that high intake of 
fructose by the vegetarians may contribute towards increase in AGE levels and 
presimiably to accelerated ageing (Krajcovicova-Kudlacova etal, 2002). 
Fructose levels in vivo rarely increase beyond those of glucose but the high 
reactivity of the former makes it a serious contributor to the glycation reactions. 
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Since it is the open chain forms of various sugars that are reactive towards the 
amino groups, those with more stable open chains are more reactive. In solution 
the open chain form of fructose constitutes over 0.7% of the total sugar as 
compared to the 0.002% of glucose- a difference of over 350-fold (Bunn and 
Higgins, 1981). 
Fructose is mainly generated through the polyol pathway in the body (Gabbay, 
1975). While in vivo fructose levels are normally quite low as compared to those 
of glucose in majority of tissues, the ketosugar can accumulate in high 
concentrations in cells that operate the sorbitol pathway (Kinoshita et al., 1979). 
For instance, in the human ocular lens, fructose concentration may rise up to 23-
fold diuing diabetes, far exceeding the concentration of glucose (Tomlinson et al., 
1994). Similar local increases in fructose concentrations have also been 
demonstrated in conditions like diabetes in peripheral nerves, blood vessels, 
erythrocytes (Poulsom et al., 1983 TombUnson, 1985) and testis (Fakuola et al., 
1989) that operate the active polyol pathway. In addition, fructation appears to 
differ from glucation in its rapid second transformation i.e. rearrangement of the 
Amadori product in Heyns kind of rearrangement presumably due to the high 
reactivity of the resulting Amadori product (Suarez etal., 1989). 
Bunn and Higgins (1981) in an earlier study have shown that the rate of Schiff 
base formation between hemoglobin and fructose was 7.5 times faster than that 
with glucose. Suarez et al., (1995) reported in a more recent study that fructated 
BSA is clearly more resistant to degradation by an ATP-dependent proteolytic 
system than the glucated protein due to the formation of higher amount of 
Maillard fluorophore. Since fructose is more active in glycation reactions and s-
aminogroup of lysine and a-amino groups, which are modified by glycation, have 
been impHcated in ubiquitination and ATP dependent proteolysis (Hershko et al., 
1984), the observation was not imanticipated. Sakai et al., (2002) observed that 
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fructose is more readily degraded to dicarbonyl compounds in solution as 
compared to glucose. 
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Fig. 4. The early reactions of proteins with glucose and fructose 
Evidently, the post Amadori products of fructose, like those of glucose, are highly 
heterogeneous and complex and not yet fuUy characterized. They however seem 
to differ significantly from Amadori products generated during glucation (Suarez 
et al , 1989; McPhereson et al., 1998) 
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1.2.2, Glycation by ribose 
As compared to glucose and fructose the pentose sugar ribose was fovmd most 
potent glycating agent (Khalifah et al., 1996; Drasta et al., 2002). Ribose is a 
naturally occturing sugar synthesized in the body from glucose and is an essential 
component of ATP. Ribose also occurs in RNA, one of the main information-
carriers of living organisms. Because ATP is rapidly used by muscles in high-
intensity workouts and because RNA is important in protein synthesis, ribose 
supplements and energy drinks containing ribose are being promoted for energy 
enhancement and better exercise performance. Ribose supplements haven't been 
extensively studied, but emerging evidence does suggest that they benefit patients 
vdth congestive heart failure, a serious condition in which the heart cannot pimip 
sufficient blood to meet the body's circvdatory needs. In a recent study Omran 
(2007) reported ribose appears to improve heart function and quality of Ufe among 
these patients by increasing levels and availabihty of ATP. Preliminary evidence 
also indicates that ribose may ease the pain and fatigue of patients with 
fibromyalgia and chronic fatigue syndrome. According to the conventional dogma, 
a pentose sugar, such as ribose, reacts first with a lysine residue on proteins to form 
an Amadori product, which then reacts with an arginine residue to form 
pentosidine (Sell and Monnier, 1989). Ribose levels are expected to rise in cells of 
diabetics where the pentose phosphate pathway is enhanced. A likely 
intramolecular source of reducing sugar is ADP ribose, a recognized histone 
glycation and glycoxidation agent in vitro (Lauren et al., 1996). S)n:ovy (1994) 
compared glycation of rat skeletal muscle myofibrils with various sugars and the 
maximum decrease in the myofibrillar ATPase activity was observed by glycation 
with ribose. Incubation of hnk proteins and proteoglycans with ribose results in 
crosslinking both in vivo and in vitro (Pokharana and Pottenger, 2000). Janual et 
al, (2003) showed that covalent coupling of reduced glutathione with ribose might 
contribute to the decrease in cell GSH levels and glutathione peroxidase activity. 
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Another enzyme aspartate aminotransferase has also been shown to be inhibited 
by glycation with ribose (Drasta et al., 2002). Ribose also produces AGE ligands 
that have very high binding affinity for RAGEs (Valencia et al., 2004). 
1.3 Glycation of various biomolecules 
As compared to glycation reactions involving molecules like nucleic acid and 
Upids, protein glycation has been studied extensively showing nvunerous structural 
alterations including exposure of thiols, protein compaction, cross Unking, 
fragmentation and susceptibihty to proteolysis (Seidler, 2005). Glycation by 
various sugars of a limited nvunber of amino groups in proteins Uke hemoglobin, 
albiunin and low density Upoproteins induce number of alterations in proteins and 
loss of biological activity (Turk, 2001). These include conformational alterations, 
ejqxjsure of hydrophobic residues and thiols, loss in allosteric sensitivity (Bunn et 
al., 1970), ligand binding (McDonald et al., 1979) and receptor recognition 
(Lorenzi etal., 1994). Several enzymes undergo glycation induced loss of biological 
activity including malate dehydrogenase, glucose 6 phosphate dehydrogenase, 
glutathione reductase, glyceraldehydes-3-phoshate dehydrogenase, catalase and 
superoxide dismutase (Heath et al., 1996; Seidler, 2005; Jabeen et al., 2006). 
AGE formation can result in the modification of the functional properties of the 
key extracellular matrix molecvdes. For example, in collagen, the most abimdant 
protein in the body, AGEs induce intermolecular bonds (Monnier et al., 1996). 
Formation of AGEs on laminin, another extracellular protein, causes reduction in 
polymer self-assembly and decreased binding of other major components like type 
IV collegen and heparin sulfate proteoglycan (Makino etal., 1995; Haitoglou et al., 
1992). In diabetes mellitus, protein glycation and glucose auto-oxidation may 
generate free radicals, which in turn catalyze lipid peroxidation (Baynes, 1991). 
Crystallins are synthesiszed during lens development and retained without 
turnover and at least some of these are as old as the organism itself (Hoenders and 
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Bloemendal, 1983). They are therefore among the most svisceptible to glycation 
and nimierous studies suggest that the glycation of lens crystalUns in diabetes and 
aging results in their unfolding, aggregation and crosslinking. Yan and Harding 
(2003) have shown that y-crystalHne undergo glycation most readily and the 
primary target of glucose is y-lllb-crystallins, while that of fructose is y-llla-
crystallin. Glycation of a-crystallin caused crosslinking and high molecular mass 
aggregation along with alterations in secondary and tertiary structures (Kvmiar et 
al., 2004). High susceptibihty of the y-crystallins to glycation has also been 
reported in earlier studies (Swamy and Abraham, 1991; Smith et al., 1996). A 
report on the glycation of a-crystallins as related to their chaperone role is also 
available (Blakytyn and Harding, 1995). Yan and Harding (2006) observed that the 
glycation results in inactivation of its chaperonic function. 
As in case of proteins, DNA bases also contain amino groups that offer potential 
sites for glycation and generation of AGEs, but deoxyguanosine appears to be most 
reactive vmder physiological conditions (Thomalley, 2003). Several nucleotides 
adducts from glycated DNA have been identified (Mistry et al., 2003). The 
presence of AGE on DNA cavises imusual transpositional rearrangements (Lee and 
Cerami, 1990; Bucala et al., 1993). In addition to the damage caused to DNA by 
direct reaction with sugars, protein AGEs may exert remarkable genotoxic effects. 
Wondrak et al., (2002) have shown that glycated proteins can serve as 
photosensitizers of DNA damage. Stopper et al., (2003) have shown that AGE-BSA 
catised marked DNA damage as revealed by the comet-assay. 
1.3.1. Glycation of HSA 
HSA is the most abimdant protein in plasma that comprises about 60% of the total 
protein foxmd in blood (Shaklai et al., 1984). HSA is important for maintaining 
osmotic pressure in the circulatory system (Peters, 1996) and also plays protective 
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role as antioxidant (Coussons et ah, 1997). HSA has highly flexible structtire and 
can bind various molecules for transportation throughout the body. 
Primary, secondary and tertiary structure of HSA is well characterized. HSA 
comprises 585 amino acids with a molecular mass of 66,438 Da. It has 28 a-heUcal 
segments that comprise 67% of the secondary structure. Rest of the secondary 
structure consists of 10% p-tums and 23% extended peptide chain. The tertiary 
structure of HSA is arranged in SOxSOxSOA heart shape in three homologous 
domains I, II, 111 (Fig. 5A). It contains only one tryptophan located in domain II 
(Peters, 1996; Coussons etal, 1997; Weber, 1975). 
Trp-214 
Fig. 5A. Ribbon diagram of three dimensional structure of HSA (Mendez 
etal., 2005) 
Glycation of albumin occurs at mvdtiple sites. Glucose can be attached to Lys'^, 
Lys^*\ Lys"*^ ', and Lys^ -^  as well as at some other lysine and arginine residues, and 
also at the N-54 terminal residues of polypeptides (Iberg and Fluckiger, 1986). 
Lysine-199 is one of the major glycation sites of HSA (Iberg and Fluckinger, 1986), 
plays a key role in the binding of anti-inflammatory drug (VanBoekel et al, 1992) 
and such binding may result in a decrease in glycation of HSA with glucose 6 
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phosphate in vitro (VanBoekel et al., 1992) presumably by competitive binding to 
a favored site of glycation (Fig. 5B). 
Lyv212^  
^ ^ • V \ y^^ -i^ ^ 
"1 
Fig. 5B. Structure of HSA around Trp with three closest lysine residues 
indicated (Mendez etal., 2005) 
In diabetes, the level of glycated HSA may rise from 6-10% to 20-30% and hence 
serves as the indicator of glycation (Nakajou et al, 2003). HSA can potentially 
undergo glycation on some of its 58 lysine residues (Guthrow et al., 1979). As a 
result, glycated HSA has been proposed as a useful marker for short term 
monitering of the diabetes patients. HSA also represents the major and 
predominant circulating antioxidant in plasma known to be exposed to continuous 
oxidative stress (Soriani et al., 1994). Glucose and free radicals were found to 
impair the antioxidant properties of the serum albumin (Bourdon et al, 1999). 
HSA possesses esterase activity due to the close proximity of Arg-410 and Tyr-411 
residues (Watanabe et al, 2000). According to Nakajou et al, (2003) in vitro 
glycation of HSA with glucose causes inhibition of its esterase activity. Glycated 
and AGE modified albumin are reported to have different functional (Vlassara et 
al, 1992) and immunological properties (Makita et al, 1992) as compared to non-
glycated covmlerparts. Sattarahmady et al., (2007) reported the formation of 
molten globule state in HSA after prolonged glycation. Also glycation may results 
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in the formation of thermodynamically more stable high molecular weight 
aggregates than its unglycated forms (Khan et al., 2007) 
1.3.2. Glycation of various enzymes 
A large of number enzymes imdergoes remarkable inactivation in response to 
glycation and the mechanism of loss of biological activity has received 
considerable attention. Diverse enzymes are modified by glycation. Some enzymes 
are inactivated due to modification in their active sites. Glyceraldehyde inactivates 
pancreatic glucokinase and substrate prevents inactivation (Murata et al., 1993) 
suggesting active site modification. Fructose inactivates GADPH (Zhao et al., 
2000) suggesting that the glycolytic pathway in hexokinase containing cells may 
be at the risk of inhibition. The primary site of glycation is near the active site and 
glycation may change the microenvironment aroimd the crucial CI49 residue of 
the enzyme (He et al., 1995). Yan and Harding (1997) studied the inactivation of 
two important antioxidant enzymes catalase and superoxide dismutase resulting 
from incubation with various sugars. Ribose and fructose inactivated the enzymes 
along with their antigenicity more rapidly than glucose and glucose-6-phosophate. 
Cu,Zn-SOD is inactivated initially by glycation at Lys-122 and Lys-128, followed 
by specific as well as non-specific firagmentation (Arai etal., 1987) 
The process of glycation in vitro is slow necessitating long incubations and high 
and usually imphysiological concentration of the sugars. Derham and Harding 
(2002) have however shown that entrapment of enzymes inside the resealed 
hvunan erythrocyte ghosts that provides enzymes with a more physiological 
environment, promotes glycation. Using the system they demonstrated that 
incubation with firictose leads to a remarkable inactivation of catalase, malate 
dehydrogenase, glutathione reductase, fumerase, aldehyde dehydrogenase, lactate 
dehydrogenase, glyceraldehydes-3-phosphate dehydrogenase and superoxide 
dismutase. Glycation and crosslinking glycation products cause a decrease in 
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chaperon function of a-crystallin (VanBoekel et al., 1996; Hook and Harding, 
2002). Fructation also inhibits the human erythrocyte membrane associated Na/K-
ATPase and Na/K pimip but a-crystalline entrapped in the resealed ghosts offers 
remarkable protection against the inactivation (Derham etal., 2003) 
Bousova et al. (2005) have demonstrated that fructose glycates aspartate 
aminotransferase more readily than glucose and during glycation a good 
correlation was observed between enzyme modification and catalytic activity as 
compared to that with pentosidine AGE formation. Fructose and several other 
hexoses and pentoses have been shown to inactivate 5-aminolevuUnic acid 
dehydratase an enzyme involved in heme biosynthesis (CabeUero et al., 1998). 
Since the activity of the enzyme is low along with the other heme enzymes 
porphobilinogen deaminase and luroporphyrinogen decarboxylase in diabetics, 
glycation of 6-aminolevulinic acid dehydratase may result in lowered synthesis of 
hemoglobin (Cabellaro etal., 1998) 
A number of other enzymes have also been shown to undergo inactivation by 
various sugars but more efficiently by fructose. These include glutathione 
reductase (Blaytyn and Harding, 1995), glucose-6-phosphate dehydrogenase 
(Ganea and Harding, 2005), malate dehydrogenase (Heath et al., 1996), esterase 
(Yan and Harding, 2003), isocitrate dehydrogenase (Kil et al., 2004), alanine 
transferase (Barenek etal., 2001) and Ca^ * ATPase (Gonzalez etal., 1993). Sorbitol 
dehydrogenase occurs both in glycated and non-glycated forms and the fraction of 
later is increased diabetic liver. Fructose was remarkably more active in bringing 
about glycation and inactivation of the enzyme in vitro (Hoshi et al., 1996). 
Fructose has been to inactivate glyceraldehyde-3-phosphate dehydrogenase that 
indicates potential inhibitory effects on the glycolytic pathway (Zhao et al., 2000; 
Hook and Harding, 1992). The inhibition is significant since inactivation of the 
enzyme results in the accumulation of glyceraldehydes-3-phosphate, which is 
highly reactive in glycation reactions. 
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Extensive glycation of aspartate aminotransferase causes decreased flexibility as 
evidenced by a decrease in l-anilinonahthalene-8-suLfonate (ANS) binding 
(Seidler & Seibel, 2000). Using the same model enzyme and glyceraldehyde it was 
shown that glycation causes an increased Tm suggesting a glycation induced 
rigidification of the enzyme (Yeargans et al, 2003). Loss of enzyme activity 
correlate with increased Tm when a concentration range of glycating agent was 
tested (Seidler et al., 2000) suggesting that enzyme inhibition is due to decrease 
flexibility of the protein. The increase in the rigidity of the 3-dimentional 
structure of the glycated proteins may be in part attributed both to intra- and 
inter-molecrular crosslinking. Free amino groups from N-terminus or from lysine 
residues are required for protein crosslinking as evidenced by incubation of a-
dicabonyls (methylglyoxal, glyoxal) with lysine free peptides (that contain 
arginine) and arginine free peptides (that contain lysine) (Miller et al., 2003). 
Protein crosslinking typically accompanies the glycation-induced loss of enzyme 
activity (Morgan et al, 2002; Southwell et al, 2002) Surface of the enzyme 
contains large number of hydrophilic residues to facilitate maintainance of the 
native structure of the enzyme. AGEs are hydrophobic hence they promote a 
condensation of substructures that result in local compaction within the protein 
(Yeargans era/ , 2003). 
1.3.2.1 Glycation of RNase A 
Pancreatic RNase A is an extensively studied highly thermostable enzyme (Raines, 
1998). It is the first enzyme and third protein to be sequenced (Hirs et al, 1960; 
Smyth et al, 1963). RNase A is a small protein comprising of 124 amino acid 
residues with a molecular mass of 13,690 daltons (Pace et al, 1995). It contains all 
the natural amino acids except tryptophan. The number of tyrosines in the 
enzyme is six and the protein is crossHnked by four disulphides. The secondary 
structure consists of long four stranded antiparallel p-pleated sheets and three 
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short a-helices. The overall shape of the enzyme resembles that of a kidney 
(Fig. 6). 
Fig. 6. Ribbon diagram of tertiary structure of RNase A (Brookhaven 
protein data bank and draAvn with RASMOL) 
RNase A contains 10 lysine residues including the amino terminal residue 
(Blackburn, 1976). The two amino groups have low pKa values Lys-1 (pKa -7.8) 
and Lys-41 (pKa ~ 8.8) making them f)otentially more reactive in formation of the 
Schiff base, while the remaining lysine residues have pKa ==10.5 and are less 
reactive. Three lysine (1,7 and 41) are near or in the active site and modification 
of these three has been shown to decrease specific activity of the enzyme (Walter 
and Wold 1976). Earlier studies have described several reagents that are known to 
react preferentially with the active site lysine residues and inactivate enzyme at a 
rate much faster than overall rate of lysine modification (Richards and Wyekoff, 
1971). 
Brock et al., (2003) identified Lys-41 in the active site of RNase A as the primary 
site for glycation and carboxymethylation. Glycation of RNase has been subjected 
to detailed investigation using glucose as model sugar but several reports on the 
reaction with other sugars are also available (Booth et al., 1997). McPherson et al., 
(1988) observed that while the in vitro rate of reaction with glucose and fructose 
with RNase were comparable, covalent non-disulphide crossUnking was induced 
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10 times more rapidly with fructose. In a previovis study Arg-39 and Arg-85 were 
identified as the major sites of modification of RNase by a-dicarbonyls (Blackburn 
and Moore, 1982). Methylglyoxal, glyoxal and diacetyl also causes impairment of 
the RNase A activity (Miller and Gerrard, 2005). Irradiation of supercoiled phi X 
174 DNA with solar simvdated Ught in the presence of AGE modified RNase 
induced DNA single strand break (Wondrak et al., 2002). The metal catalysed 
oxidation of phosphoUpids in the presence of RNase led to the loss of amino 
groups in RNase and incorporation of phosphate, hexanoate, entanedioate and 
palmitate into protein (Januszewsi etal., 2005) 
1.4. Protein oxidation in diabetes 
Oxidative stress is suggested to be a potential contributor for the development of 
compUcations in diabetes (Baynes, 1991). Glycation has been considered as a 
fixative of free radical damage while glycated proteins act as free radical 
generators. Increased free radical production and reduced antioxidant defense 
responses, encovmtered in the diabetic state may give rise to increased oxidative 
stress (Halliwell & Gutteridge, 1990). Consequences of oxidative stress are 
adaptation or cell injury, i.e. damage to DNA, proteins and Upids, disruption in 
cellular homeostasis and accumulation of damaged biomolecules (Jakus, 2000). 
Under conditions of severe oxidative stress, free radical generation leads to protein 
modification. Proteins may be damaged directly by specific interactions of 
oxidants or free radicals with particularly susceptible amino acid residues. They 
may also be modified indirectly, with reactive carbonyl compounds formed by the 
auto-oxidation of carbohydrates and lipids, with eventual formation of advanced 
glycation/lipoxidation end products (Gtunieniczek, 2005). 
Diabetic patients exhibit elevated levels of intracellular iron and copper ions 
which in the presence of glycated proteins, have been shown to enhance the 
generation of free radicals//: vitro (Dean etal., 1991). These highly reactive species 
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in turn are able to induce oxidative degradation of protein in vitro (Pacifici and 
Davies, 1991). Interestingly, metal-catalysed glycoxidative pathways were 
described to involve hexoses as possible preairsors, in addition the to pentoses 
(Chace et al., 1991; Dyer etal., 1991). Under in wVo conditions, Cu^ * and Fe^ are 
the most important metal-ion catalysts of the oxidative reactions. In blood plasma 
and in cellular cytoplasm virtually all of these ions are sequestered in specific 
metal transporters and other metalloproteins (Evans etal., 1989; Rae etal., 1999). 
However, copper metalloproteins such as ceruloplasmin and Cu- Zn superoxide 
dismutase and the iron metalloproteins such as hemoglobin and myoglobin have 
been shown to undergo significant conformational change and even firagmentation 
diiring glycation reactions, causing the release of bound metal (Takata etal., 1996; 
Cussimanio etal., 2003). 
1.5. Pathogenedty of glycation and AGEs 
Glycation cytotoxicity is the result of: (a) inhibition of specific functions of 
proteins; (b) cross-linking, aggregation, and precipitation of proteins; and (c) 
production of reactive oxygen species. AGEs have been shown to be intimately 
involved in the pathology of many diseases, including diabetes,(Metz et al., 2003), 
inflammatory diseases, (Anderson and Heinecke, 2003), atherosclerosis and heart 
failure, (Zieman and Kass, 2004), macular degeneration (Howes et al., 2004), 
osteoarthritis ( DeGroot et al., 2004), rhevunatoid arthritis (Drinda et al., 2004), 
Alzheimer's disease (Choei et al., 2004 and Lueth et al., 2004), poor bone healing 
(Santana et al., 2003), cataracts (Nagariaji et al, 2002) and kidney disease 
(Alderson etal., 2003). AGEs are especially accumulate on long-lived proteins such 
as collagen, the most abundant protein in the body, which makes up a significant 
part of skin, bones, cartilage, tendons, teeth and the cardiovascular system. AGEs 
cross-Unk various proteins, making them stiffer and less elastic. They damage 
normal three-dimensional protein structure, inhibit the physiologic function of 
proteins, and trigger inflammatory reactions. These stable compounds (AGEs) 
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accumvilate slowly throughout the lifespan and contribute to structural and 
physiologic changes in the cardiovascular system such as increased vascular and 
myocardial stiffiiess, endotheUal dysfunction, altered vascular injury responses, 
and atherosclerotic plaque formation (Zieman and Kass, 2004). An overview of the 
role of protein glycation in the development of diabetic complications is presented 
below. 
Diabetes 
Increased glycation and AGEP formation 
1 I 
Proteins DNA 
I 
LDL 
I 
j Growth 
J Factors 
Chronic complications of diabetes mellitus 
"T \ I I r 
Neuropathy Retinopathy Atherosclerosis Nephropathy Cancer 
Fig. 7. Effect of enhanced AGE formation in diabetic complications 
(Ahmad and Ahmed, 2006) 
AGEs are a major causal contributor to aging and the diseases of aging but 
unfortvmately, there are few enzymes in the body that effectively break down the 
AGEs and their pathologic and imwanted cross-links in proteins. Glycation of 
proteins, Upids, and nucleic acids may play an important role in the natural 
processes of aging. Protein glycation has been associated with beta-amyloid 
deposits and formation of neiu-ofibrillary tangles in Alzheimer disease, and 
possibly other neurodegenerative diseases involving amyloidosis (Colaco and 
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Harrington, 1994). Glycated proteins have also been shown to be toxic, antigenic, 
and capable of triggering cellular injxiry responses after uptake by specific cellular 
receptors (Vlassara et al., 1994, Daniels & Hauser, 1992, Brownlee, 1994, Cohen et 
al., 1994, Brett et al.. 1993 and Yan et al., 1994). The group of glycation products 
consists of many different structures. They induce many cellvilar responses by 
binding to a specific receptor for the AGEs. AGE-HSA inhibits the proliferation of 
vascular endotheUal cells and induces apoptosis in dose and time dependent 
manner (Lin etal., 2003). 
1.6. Assays of glycation 
Considering the important role of glycation in causing damage to various tissues 
and organs, assays of glycation have received remarkable attention. In clinical 
practice the AGE measurement offers direct means of monitoring its accvunulation 
in various tissues for use as prognostic marker and in evaluating the efficacy of 
various therapies. The development of methods based on high pressure Uquid 
chromatography (HPLC) allows the detection of glycation. Mc Pherson et al., 
(1988) used a procedxure based on HPLC analysis of phenylthiocarbamoyl 
derivative of glycated proteins followed by calculation of position of C-1 and C-2 
of hexose covalently bound to proteins. Analysis of glycated amino acids showed 
that 85% of the attached hexose is connected to e-amino groups of lysyl residues 
via carbon 2(C-2) of the hexose chain and the remainder being connected via C-1. 
Ahmad et al., (1986) identified CML in himian lens and tissue collagen by HPLC 
which was confirmed by gas chromatography mass spectrometry. They observed 
that the oxidative degradation of Amadori adducts with proteins occur in vivo that 
leads to the formation and excretion of CML and lactic acid. However this 
procedure is complicated for routine analysis especially for in situ detections. 
Earlier studies employed strategies based on variovis chromatographic methods 
using the specific interaction of boronate ligands with the cis-diols of glycated 
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proteins and these continued to be widely used for measviring glycated proteins 
(Furth, 1988). 
Another approach for the qtiantification of AGE is an immunological assay 
(Makita et al., 1992). Mitsuashi et al. (1997) had shown the immvmological 
recognition of AGE by competitive ELISA and also suggested that in vitro 
modified proteins might not be appropriate standards for AGE that occur naturally 
in vivo. The lack of available certified glycation standards hamper standardization 
of various methods discussed. Miyazawa etal. (1998) isolated a novel antibody that 
exclusively recognizes fructated proteins but not adducts formed fi*om other 
sugars. This method is simpler and more convenient than other quantitative 
detections of finctated proteins as there is no specific reliable method to detect 
glycation with fiiictose. Some of the hterature results are based on the use of 
polyclonal and monoclonal AGE antibodies (Nagai and Horiuchi, 2003). 
Radioimmimoassay (RIA) (Sheikh and Robb, 1993) and enzyme linked boronate 
immunoassay (ELBIA) (Ikeda et al., 1998) based methods are also available to 
evaluate the glycation levels of intact proteins and their hydrolysis products. For 
in vivo detection of AGEs, immunohistochemical methods have been employed 
(Hayashi et al., 2002). However all the existing procedures are time consiuning 
requiring several hours to obtain results. 
Some spectroscopic methods for detection of glycation levels in the various 
substrates of interest are also available (Odetti et al., 1990). The glycation level of 
plasma proteins have been evaluated by measuring fructosamine levels with the 
help of a colorimetric assay based on the ability of ketoamine to reduce the nitro 
blue tetrazoUum dye (Johnson et al., 1983). Kobayashi et al. (1993) measured 
glycated albumin by a method based on colorimetry of ketoglucose released from 
glycated protein (ketoamine) on heating with hydrazine. Another procedure that 
uses thiobarbituric acid (TBA) is based on the estimation of a complex formed by 
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the reaction of TBA with S-hydroxymethyl furfural which is released by the 
dehydration of sugar in boiling oxaUc acid (Ney et al, 1981). Sensi et al., (1988) 
developed a procedure in which the glycated proteins are treated with sodium 
nitrite and sulfianilic acid followed by the addition of sodium hydroxide to 
facihtate the formation of a chromophoric diazonivmi salt that absorbs maximally 
at 492 lun. 
Among the existing protein glycation assays the quantification of Amadori product 
via periodate remains most convenient. This method was first proposed by Gallop 
et al., (1981) for the quantification the glycation in hemoglobin and later on 
adapted using a microplate reader for sensitivity enhancement. Another important 
improvement was achieved by reducing proteins with sodium borohydride before 
periodate oxidation to decrease the interference by serum glycoproteins. The 
terminal reducing sugars of glycoproteins cause excessive background noise in the 
assay (Ahmad and Furth, 1991). Ahmed and Furth (1992) observed that in spite of 
the high fluorescence exhibited by the fructated proteins, the enhancement was 
reflected neither in the fructosamine nor phenylboronate affinity glycation assays. 
The underestimations were striking with the fructosamine assays that suggested 
only about 5% formation of fructosamine of that induced by glucose, while the 
phenylboronate affinity assay showed the glycation by fructose to be only 25%. 
The thiobarbutyric acid and periodate based assays were also shown to greatiy 
underestimate the glycation caused by fructose (Ahmed and Furth, 1992). Syrovy 
(1994) compared various colorimetric methods and foimd the extent of glycation 
by various sugars by one method does not correspond well with the restilts 
obtained by another one. 
Advanced glycation endproducts are also determined by 'total AGE fluorescence'. 
Avendano et al., (1999) characterized AGE specific fluorescence in collagen by 
measuring emission at 440 nm following excitation at 370 nm. Increase in brown 
pigment formation and fluorescence was observed with the advanced glycation of 
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long lived tissue proteins such as lens crystallin, collagen and myelin (Avendano et 
al, 1999; Sajithlal et al, 1998). Fluorimetric methods are compromised due to 
several analytical problems, as the major AGEs in biological systems are non 
fluorescent and therefore not detectable. The estimation of total AGE fluorescence 
is currentiy used as representative of qualitative measure of damage by glycation 
adduct fluorophores. Now a days spectroscopy is widely employed in conjugation 
with analytical methods like HPLC (Wilker et al., 2001). Other commonly used 
spectroscopic techniques for the detection of glycation induced changes either in 
protein or sugar structure are CD (Bovraia etal., 2003), IR spectroscopy (Khajehour 
et al., 2006) or NMR (Howard and Smales, 2005). Presence of sugar complicates 
the determination of protein structure by conventional technique like X-ray 
crystallography. NMR studies have been successfully used for small glycated 
peptides, however solving the structure of glycated protein by NMR is however 
problematic as the increase in rotational diffusion causes a line broadening effect 
(Howard and Smales, 2005). Khajehpour et al., (2006) used IR spectroscopy to 
moniter the alterations in the sugar moiety in glycated proteins. 
Mass spectrometry has been effectively employed in studies on protein glycation 
and the high quahty of result makes its use of particular interest (LapoUa et al., 
2001). In addition to in vitro glycation determination, MALDI can also be vised for 
in wVo glycated samples (LapoUa etal., 2006). Stefanowicz et al., (2001) evaluated 
high temperature glycation of proteins and peptides by electrospray ionization 
mass spectrometry. Wa et al, (2007) studied the drug binding sites that are 
modified in albiimin by glycation by MALDI time of flight mass spectrometry. 
The technique is based on a unique sugar moiety neutral loss that was observed in 
the fragmentation spectra of glycated peptides on Q-Tof type mass spectrometers. 
All three sugar moieties displayed characteristic fragmentation patterns 
accompanying the parent and the fragment ions, which could be explained by 
consecutive losses of water and formaldehyde. A reversed phase liquid 
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chromatography followed by neutral loss scan mass spectrometric methods is 
developed by Gadgil et al., (2007) for the screening of glycation in proteins. Gadgil 
et al., (2007) identified 31 lysine glycated residues from total 59 lysine residues 
present in HSA. 
Fluorescence 
Alkaline reduction 
and Fructosamine 
Ion-exchange 
chromatography 
MALDl 
Glycated 
proteins 
Pyrolysis 
GS/MS 
Mass 
Spectrometry 
Thiobarbituric 
assay Furosine 
Acid or 
Enzymatic 
hydrolysis 
FAB 
HPLC/MS 
MS/MS 
GC/MS 
Carboxymethyl-lysine 
Fig. 8. Analytical approaches for the quantification of glycated proteins 
(LapoUa etal., 2000) 
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1.7. Prevention of glycation 
1.7.1 Natural defence 
Body has several humoral and cellular defence mechanisms to protect tissues from 
deleterious effects of glycation reaction and AGE accumulation. These include the 
glyoxalase systems (1 and II) that catalyses the deglycation of methylglyoxal (MG) 
to D-lactate (Thomalley, 1990; Thomalley, 1998). Other enzymes involved in the 
regulation of AGE formation are oxoaldehyde reductase and aldose reductase that 
detoxify reactive dicarbonyl intermediates (Boel et al., 1995; Vanderjagt et al., 
2001). 
Additionally, a novel class of enzymes called as amadoriases were fovmd that 
reverses the initial stage of the Maillard reaction between glucose and primary 
amines. The discovery of deglycating enzymes has implications for the repair of 
protein damage by fructose (Monnier, 2005). Another enzyme identified in 
erythrocytes, Fructosamine-3-kinase, catalyses the phosphorylation of protein 
boimd fructosamine on their third carbon and leads to its destabilization and 
removal from protein (Collard etal., 2004). 
Receptors present on macrophages enable them to recognize and remove harmful 
AGE-proteins by endocytosis (Vlassara et al., 1985). A variety of plasma amines 
may react with sugar and Amadori carbonyl groups to decrease the formation of 
AGEs. Antioxidants can protect biomolecules against the free radicals generated 
by glycation whereas transport proteins, for example, ceruloplasmin can bind 
transition metals such as cupric ions, preventing them from participating in 
autoxidative glycation or glyoxidation reactions. 
1.7.2 Synthetic and natural inhibitors 
Discovery and design of inhibitors for the glycation reaction should offer a 
promising therapeutic approach for the prevention of diabetes or other pathogenic 
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complications. Currently several strategies are employed to control protein 
glycation. Most of the inhibitors have several sites of action. Some drugs have been 
specifically developed as AGE inhibitors or AGE breakers, RAGE and receptor 
signaling blockers. A number of therapeutic compounds are found to possess AGE 
inhibitory activity (Fig. 9). 
The first compound that has been extensively studied in vitro and in vivo to be a 
powerful inhibitor of AGE formation is aminoguanidine (AG) (Brownlee et al., 
1986). AG prevents the formation of fluorescent AGEs and glucose derived 
collagen crosslinking. The mechanism of inhibition of AGE formation by AG 
involves trapping of reactive dicarbonyl intermediates such as MG, glyoxal and 3-
DG (Thornalley et al., 2000; Thomalley, 2003). In addition to chelating or 
antioxidant activity, AG also acts as true scavenger of carbonyl compounds 
(Thornalley et al., 2000). OPB-9195, a hydrazine derivative similar to AG also 
inhibits pentosidine generation from diabetic plasma (Miyata et al., 1998). 
Unfortunately, the clinical trials of this compound were hampered due to side 
effects related to the trapping of pyradoxal which results in vitamin B6 deficiency 
syndrome (Miyata et al, 2005). Pyradoxamine, a form of vitamin B6, found to 
inhibit CML formation in vitro but it does not interact directly with Amadori 
intermediates but interfere with the post Amadori oxidative reactions by binding 
catalytic metal ions (Voziyan et al, 2003; Chatyrkin et al., 2008). It also traps 
reactive carbonyl compounds derived either from the sugars or lipids (Onarato et 
al, 2000; Voziyan et al, 2002). A lipophillic derivative of thiamine (vitamin Bl), 
benfotiamine was also found to prevent vascular accumulation of AGE. Its 
proposed mechanism of action involves shunting of triose glycolytic intermediates 
towards the reductive pentose pathway (Babai-jadidi et al, 2003). It also reduces 
aldose reductase mRNA expression and intracellular glucose and sorbitol levels 
(BerroneefaZ, 2006). 
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Fig. 9. Potential sites of inhibition of AGE formation and AGE-mediated damage 
(Peyrous and Sternberg, 2006) (1) trapping of reactive dicarbonyl species; (2) 
antioxidant activity by transition metal (M2+) chelation; (3) other antioxidant 
activity including free radical scavenging; (4) AGE cross-link cleavage (by AGE 
breakers); (5) AGE receptor (RAGE) blocking; (6) AGE receptor (RAGE) signaling 
blocking; (7) glycemia reduction by anti-diabetic therapy; (8) aldose reductase 
inhibition; (9) shunting of trioses-P towards the pentose-P pathway by 
transketolase activation. 
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The first compound that has been extensively studied in vitro and in vivo to be a 
powerful inhibitor of AGE formation is aminoguanidine (AG) (Brownlee et al., 
1986). AG prevents the formation of fluorescent AGEs and glucose derived 
collagen crosslinking. The mechanism of inhibition of AGE formation by AG 
involves trapping of reactive dicarbonyl intermediates such as MG, glyoxal and 3-
DG (Thomalley et al., 2000; Thomalley. 2003). In addition to chelating or 
antioxidant activity, AG also acts as true scavenger of carbonyl compounds 
(Thomalley et al., 2000). OPB-9195, a hydrazine derivative similar to AG also 
inhibits pentosidine generation from diabetic plasma (Miyata et al., 1998). 
Unfortunately, the clinical trials of this compound were hampered due to side 
effects related to the trapping of pyradoxal which results in vitamin B6 deficiency 
syndrome (Miyata et al., 2005). Pyradoxamine, a form of vitamin B6, fovmd to 
inhibit CML formation in vitro but it does not interact directly with Amadori 
intermediates but interfere with the post Amadori oxidative reactions by binding 
catalytic metal ions (Voziyan et al., 2003; Chatyrkin et al., 2008). It also traps 
reactive carbonyl compounds derived either from the sugars or Hpids (Onarato et 
al., 2000; Voziyan et al, 2002). A lipophiUic derivative of thiamine (vitamin Bl), 
benfotiamine was also found to prevent vascular accumulation of AGE. Its 
proposed mechanism of action involves shunting of triose glycolytic intermediates 
towards the reductive pentose pathway (Babai-jadidi et al., 2003). It also reduces 
aldose reductase mRNA expression and intracellxdar glucose and sorbitol levels 
(Berroneefa/.,2006). 
Recently two new classes of aromatic compounds, derivatives of aryl (and 
heterocycUc) ureido and aryl (and heterocycUc) carboxamido-phenoxy-isobutyric 
acids and benzoic acids have been reported to be potent inhibitors of glycation and 
AGE formation (Rahbar and Figarola, 2003). In vitro studies showed that they 
could directly interact with several reactive dicarbonyls such as glyoxal and 
methyl glyoxal. They were also found to be potent chelators of Cu^ * and therefore 
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can suppress hydroxyl radical production during sugar autoxidation and glycation 
reactions (Rahbar and Figarola, 2003). 
Many studies suggested that metal catalyzed oxidation plays a critical role in 
glucose induced modification in collagen. Transition metals like Cu^ * ions can 
catalyze both glycation and glycoxidation in concentration dependent manner 
(Sajithlal et al., 1999). In earUer experiments Wells-Knecht et al., (1995) 
demonstrated that DETAPAC and EDTA act as metal ion chelators thereby 
sequestering firee metal ions in vivo. 
Camosine appears to possess antiglycating, antioxidant and firee radical scavenging 
activity. Camosine inhibits inactivation and crosslinking of enzymes including 
superoxide dismutase glycation (Ukeda et al., 2002) and oxidation (Stvolinskii et 
al., 2003). It was fovmd recently the imidazolium group of histadine on camosine 
stabilizes the adduct formation at the primary amino group and hence it may play 
an important role for an anti crosslinking agent (Hobart et al., 2004). Other 
compotinds having AGE inhibitory activity are D-pencillamine and desferoxamine 
related to their antioxidant properties (Keita et al., 1992; Jakus et al, 1999). Some 
anti-inflammatory compoimds such as acetylsaUcyUc acid, ibuprofen 
indomethacin were also reported to inhibit glycation by preventing the oxidative 
stress associated with the formation of AGE (Sobal and Menzel, 2000; Shastri etal., 
1998; Caballero et al., 2000). Aspirin was also found to inhibit pentosidine 
formation (Fu et al., 1994; Urios et al., 2005) while Diclofenac, a non steroidal 
anti-inflammatory drug was shown in vitro to be an inhibitor of AGE formation, 
presxmiably by a non covalent interaction of the drug with serum protein (Van 
BoekelefaZ, 1992). 
A large nim[iber of other compoimds have been designed and synthesized as AGE 
inhibitors. Some antidiabetic drugs metformin and progiatazone were also 
reported to be powerfiil AGE inhibitors (Rahbar, 2000). AL T -711 analog N-
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phenacyl thiazoliiun chloride claimed to catalytically break AGE crosslinks 
between proteins (Mentink, 2002). 
Other approaches for the prevention of AGE mediated damage include (i) trapping 
of circulating AGE before they bind to their receptors (ii) inhibition of interaction 
of AGE with its receptor (iii) inhibition of signal transduction mediated by the 
activation of AGE receptor (Kim et al., 2005). The prototype drug for trapping 
AGE ligands is soluble RAGE, which is the modified form of RAGE that constitute 
extracellular ligand binding domain (Wendt et al., 2003). Another endogenous 
system for trapping AGE is lysozyme that has been reported to accelerate renal 
AGE clearance (Zheng etal., 2001). 
Yet other class of inhibitors includes aldose reductase inhibitors (ARI). Under 
hyperglycemic conditions excess glucose is metabolized into sorbitol by AR 
pathway. The fructose formation in this pathway leads to 3-deoxyglucozone and 
methyl glyoxal (Fig. 9), that may accelerate formation of AGEs. Sorbinil an ARI 
were found to decrease AGE related fluorescence in skin collagen of diabetic rats 
(Suarez etal., 1988). 
More recently, researchers have been investigating molecular chaperones for 
protection against glycation-induced inactivation (Ganea and Harding, 1995; Yan 
and Harding, 2003). Molecular chaperones not only assist during protein folding 
but also stabilize proteins and prevent aggregation (Hendrick and Hartl, 1993; 
Becker and Craig et al., 1994).a-Crystallin, a molecular chaperone and lens 
structural protein, exhibit protection against glycation induced inactivation of 
enzymes Hke glucose-6-phosphate dehydrogenase, malate dehydrogenase and 
esterase (Ganea and Harding, 1995; Heath et al, 1996; Yan and Harding, 2003). 
When incorporated into red cell ghosts a-crystaUin protects membrane enzyme 
Na/K-ATPase against glycation and preserves its activity upon exposure to MG, 
fructose and H2O2. It is believed that a-crystallin may act through dynamic 
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interactions, such that the chaperone may prevent the further unfolding but not 
bind to the target protein (Derham etal, 2003). 
Recent studies have highlighted the possible benefits of using plant extracts for 
decreasing glycation over the currently vised drugs (Rates, 2001). Flavonoids 
represent the most common and widely distributed group of plant phenoUcs 
(Harbome, 1986) and are abimdant in foods. They show important antioxidant 
and AGE inhibitory properties according to their structure (Odetti et al., 1990; 
Farrar et al., 2007). Quercetin and rutin are the most abvmdantly consimied 
flavonoids. Rutin with its free radical scavenging capabiUty reduced the formation 
of glycated haemoglobin and increased haemoglobin levels in diabetic rats 
(Elgawish et al., 1996). Nagasawa et al., (2003) have shown that rutin and G-rutin 
(a water soluble rutin analogue) suppressed the formation of initial as well as 
advanced stages of Maillard reaction in tissues. Rousselot (2004) stated that 
improved antioxidant status is one mechanism by which dietary antioxidant 
treatment contributes to the prevention and reduction of diabetic compUcations. 
Quercetin has been shown to attenuate diabetic nephropathy in streptozotocin-
diabetic rats (Anjaneyulu and Chopra, 2004). Nvunerous other studies indicat that 
dietary supplementation with antioxidant nutrients may be a safe and simple 
compliment to traditional therapies for preventing and treating diabetic 
complications (Ruhe and McDonald, 2001; Jung etal., 2008). 
Some herbal extracts and compoimds isolated there form have been investigated 
for their potential against secondary complications of diabetes (Halaer et al., 2003; 
Suryanarayana et al., 2004). Green tea, a popular drink worldwide is foimd to 
contain large amount of tannins which are known for their antioxidant properties. 
Vincen and Zhang (2005) have shown that the extract can also delay diabetic 
complications. Another rich polyphenol containing extract from plant Ilex 
paraguariensis have been shown to inhibit in vitro formation of AGEs (Lunceford 
and Gugliucci, 2005). Garcinol, isolated from Garcinia indica fruit rind has been 
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shown to possess antiglycating property in vitro along with antioxidant and metal 
chelating properties (Yamaguchi et al., 2000). Mizutani et al„ (2000) isolated 
resveratrol, a natural phytoestrogen fovmd in grapes which is found to inhibit AGE 
induced proliferation and collagen synthesis in vascular smooth mviscle. Studies 
revealed that a natural compound curamiin isolated from Curcuma longa was 
shown to be a potant inhibitor of AGE formation and crossUnking of collagen in 
diabetic rats. A new compound puerariafuran isolated from the roots of Pueraria 
lobata was fovmd to be active in causing inhibition of glycation (Jang et al., 2006/ 
Cyperus rotundus suppresses AGE formation and protein oxidation in a model of 
fructose-mediated protein glycoxidation (Ardestani etal., 2007). 
1.8. Objective of the study 
Glycation, the sequence of of non-enzymatic reactions taking place between 
reducing sugars and the nucleophilic groups of proteins and other biomolecides, is 
ubiquitous and occurs in the cells of all Hving organisms, albeit at a very slow rate. 
The rates of glycation however increase remarkably dvuing hyperglycemia, in 
diabetes and related disorders. Glycation is also accompanied by the formation of 
highly reactive and damaging reactive oxygen species (ROS). A nvmiber of proteins 
have been shown to undergo structural modifications and loss of biological 
function as a result of glycation. Several enzymes including those involved in 
antioxidant defense are also inactivated leading to serious disturbance in 
metabolism and exacerbate the damaging effect of glycation. 
Available evidence suggests that agents that interfere with glycation reactions may 
be beneficial in restricting the complications accompanying diabetes and related 
disorders. Restriction/prevention of glycation and oxidative stress is therefore 
mooted as an effective strategy for alleviation of complications associated with 
hyperglycemia. 
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A number of drugs including aminoguanidine and betiiiotamine are being 
investigated as potential antiglycation compound. Molecular chaperones and 
antibodies have also been investigated for their possible protective role against 
glycation. However no single compound seems to emerge as the perfect drug for 
combating glycation. Several plant extracts and compounds derived from plants 
have shown remarkable promise in this regard. Screening of a number of plants for 
inhibitors of glycation has therefore been imdertaken by a number of 
investigators. While a large number of procedures are available for assay of 
glycation, majority of these are time consuming, necessitate speciahzed and 
expensive reagents and equipment. The objective of the work was to evaluate 
convenient, inexpensive assay procedtures for the rapid screening of inhibitors of 
glycation from various crude preparations. PossibiHty of using HSA and RNase A 
as model proteins was investigated with glucose, fructose and ribose as the reactive 
sugars. High thermostabihty of RNase A faciUtated carrying out of the assay at 60° 
C together with the highly reactive ribose, cut down of the duration of the activity 
based assay. The assay covdd be further improved by using immobilized RNase A. 
Also anti-RNase A antibody supports were shown in the study to protect the 
enzyme against inactivation caused by glucose, fructose or ribose. 
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2.0. MATERIALS 
Chemicals and reagents used in the present studies were obtained from the sources 
as detailed below. Glass distilled water was used in all the experiments. 
Sigma Chemical Co.. U.S.A. Acetyl acetone, Acrylamide, Aminoguanidine, 
Bovine pancreatic RNase A, Bovine serum albiunin 
(BSA), Catechin, Coomassie briUiant blue R-250, 
CM-cellvilose, Diethylenetriamine acetic acid 
(DETAPAC), Guanidinum HCl, Human serum 
albmnih (HSA), Myricetin, Naringin, Nitroblue 
tetrazolium (NBT), Quercetin, Rutin, Tris 
(hydroxymethyl amino-methane). 
Sisco Research Lab.. India 
Qualigens Fine Chemicals. 
India 
Difco Laboratories Detroit. 
USA 
E. Merck. India 
Genei Pvt Ltd. Bangalore 
Agarose, Ammonium per sulphate. Ammonium 
sulphate, Bromophenol blue, Cyanogen bromide, 
DEAE-cellvdose, Ethylene diamine tetraacetic acid 
(EDTA), Glucose, Folin's Ciocalteu's phenol reagent, 
Formaldehyde, Fructose, Hydrogen peroxide, 
Lanthanvun chloride, o-diansidine hydrochloride. 
Perchloric acid. Peroxidase, Ribose, Sepharose 4B, 
Sodivun borohydride. Sodium periodate. 
Trichloroacetic acid (TCA), TEMED, Yeast RNA. 
Acetic acid. Acetone, Acetonitrile, Copper sulphate. 
Diethyl ether, Di-hydrogen sodivmi phosphate, Di-
sodium hydrogen phosphate, Ethanol, Glycerol, 
Hydrochloric acid. Magnesium chloride, p-
mercaptoethanol. Potassium dichromate, Silver 
nitrate, Sodium acetate. Sodium bicarbonate, Soditun 
carbonate, Sodium chloride, Soditun hydroxide, 
Sodiiun metaperiodate. Sodium potassivun tartarate, 
Sodiimi lauryl sulphate, Svdphvuic acid, Tetra 
hydrofuran. Trichloroacetic acid, Tween-20, Zinc 
chloride. 
Freund's complete adjuvant, Frevmd's incomplete 
adjuvant. 
Ammonium sulphate, Glycine, Methanol. 
Goat anti-rabbit immuno-globulin, horse raddish 
peroxidase. 
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3.0 METHODS 
Commercial HSA and RNase A that gave single band in SDS-PAGE were vised 
without purification. Lyophilized HSA and RNase A were reconstituted with 
20mM phosphate buffer pH 7.2 to make a stock solution of 10 mg/ ml and stored at 
-20°C. 
3.1 Glycation reactions 
3.1.1 in vitro glycation with various sugars 
In order to induce glycation, the protocol used by Miyazawa et al. (1998) was 
adopted with sUght modifications. HSA and RNase A were subjected to glycation 
with fiiictose, glucose or ribose. The proteins concentration was taken as (1 
mg/ml) in 20 mM sodium phosphate buffer, pH 7.2 with respective sugar at the 
final concentration of 100 mM. The reaction mixtures were prefiltered through a 
nitrocellulose filter 0.2 |ma pore-sizes and incubated in preautoclaved tubes in 
order to maintain sterile conditions dvuing incubations. The incubations were 
carried out in the shaking water bath at 37°C for the indicated durations. Samples 
incubated without sugar similarly served as control. Each sample was extensively 
dialyzed against the buffer in order to remove excess of sugars before further 
analysis. 
3.1.2 In vitro glycation of HSA and RNase A with fructose along with various 
compoimds/drugs 
HSA and RNase A (1 mg/ml) was incubated with 25 mM DETAPAC, EDTA, 
aminoguanidine, aspirin, paracetamol, pencillamine, ibuprofen and ascorbic acid 
in the presence of 100 mM fructose. The incubations were carried out in the 
shaking water bath at 37°C for 8 days. Samples incubated without sugar under 
similar conditions served as control. Before further analysis each sample was 
extensively dialyzed against the buffer in order to remove excess of sugars. 
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3.1.3. In vitro glycation of HSA and RNase with fructose along with various 
flavonoids 
HSA and RNase A (1 mg/ml) was incubated with 10 pM quercetin, naringin, rutin, 
catechin and myrecetin in the presence of 100 mM fructose. The incubations were 
carried out in the shaking waterbath at 37°C for 8 days. Samples incubated 
without sugar tmder the similar conditions served as control. Before further 
analysis each sample was extensively dialyzed against the bviffer in order to 
remove excess of sugars. 
3.1.4. Incubation of soluble and immobilized RNase A with sugars 
In order to induce glycation, soluble RNase A or that immobilized on antiRNase 
support or CM-Cellulose support was incubated along with 500 mM glucose, 
fructose or ribose in 20 mM phosphate buffer pH 7.2 containing 5 i^M gentamycin 
to prevent any microbial growth. The reaction was carried out in a shaking water 
bath at 37°C for 8 days. After completion of incubation RNase A immobilized on 
the antibody-support or CM cellulose was eluted with 100 mM glycine/HCl buffer 
pH 3.0 and 100 mM NaCl followed by dialysis against phosphate buffer pH 7.2. 
3.1.5. Glycation of RNase A at 60 ° C 
RNase A (1 mg/ml) was incubated with 500 mM glucose, fructose or ribose in 20 
mM phosphate buffer pH 7.2 at 60 ° C for a period of 1, 2 and 4 days under sterile 
conditions. The incubations carried out under sterile condition but also contained 
5 |iM gentamycin. Where indicated RNase A was incubated with the inhibitors 
(25 mM) or plant extracts in the presence of 500 mM ribose. Control samples were 
incubated under similar conditions but without ribose or inhibitors. Similarly, 
RNase A was incubated with some plant extracts along with 500 mM ribose and 
incubated for 2 days imder similar conditions. The plant extracts were prepared by 
homogenizing garlic, ginger, grapes, bitter gourd, numeric and tomato in 20 mM 
phosphate buffer pH 7.2 followed by centrifligation. Green tea extract was 
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prepared by stirring Ig of green tea with 20 ml of 50% (v/v) ethanol for 3 h. The 
mixture was centrifuged at 1500g for 15 min and the supernatant was used as a 
source of inhibitor (Zhang et al., 2006). All the extracts were adjiisted to assay pH. 
While using immobilized RNase A, the preparation was separated for the reaction 
mixture by centri^gation and washed thoroughly, after incubation with the sugar 
and extracts prior to the enzyme activity measurements. 
3.2. Colorimetric/Spectrophotometric analysis 
3.2.1. Determination of protein concentration 
Protein was estimated by the method of Lowry et al. (1951). Aliquots of protein 
solution were taken in a set of tubes and final volume made up to 1 ml with 0.01 
M sodiiun phosphate buffer, pH 8.0. Five ml of alkaline copper reagent (containing 
one part of 0.5% (w/v) copper sidphate, 1% (w/v) sodium potassivun tartarte and 
fifty parts of 2% (w/v) sodium hydroxide) was added, followed after 10 minutes of 
incubation at room temperature with 0.5 ml of 1.0 N Folin-Ciocalteu's phenol 
reagent. The tubes were instantly vortexed. The colovir developed was read at 660 
nm after 30 minutes against the reagent blank. A standard curve was prepared 
using BSA as standard. 
3.2.2. Determination of protein bovmd carbonyl groups 
Protein -bovmd carbonyl groups were estimated according to the protocol of 
Levine et al., (1990); briefly 200 ^l aliquot containing 0.1 mg of protein was mixed 
with 400 ^1 of 7 mM DNPH in 2 M HCl. The mixtures were run in duplicate and 
the control protein samples were devoid of DNPH. After incubation for 1 hour at 
room temperature the DNPH-hydrazones were precipitated by adding 500 \i\ of 
TCA (4% w/v), centriftiged for 5 mins at 14,000 x g and the pellet dispersed in 
ethanol-ethylacetate (1:1 v/v), in order to remove unreacted DNPH. After 4 such 
washes, the pellet was resuspended in 0.6 ml of 6 M guanidiniimi HCl solution in 
20 mM phosphate buffer, already adjusting to pH 2.3 with trifluoroacetic acid. The 
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hydrazones were dissolved completely only by freezing overnight at -20°C and 
thawing. From the solution, 200 y\ aliquot was taken into a microplate and read at 
379 nm. The restdts were e3q)ressed as the niunber of moles of carbonyl per mole 
of sample protein using a 8379nin= 22000 M'cm' . 
3.2.3. Borohydride-periodate assay of glycated proteins 
A previously described borohydride-periodate assay (Kennedy et al., 1993) was 
vised Avith few modifications. 100 }il of the samples were incubated for 1 hour at 
37°C with 20 fd of 0.2 M sodium borohydride in ice cold 0.01 mM NaOH. The 
reaction was stopped by adding 20 jil of 0.2 M HCl. After this step, samples were 
incubated with 20 ^1 of 0.1 M sodivmi periodate for 30 min at 37''C followed by 
addition of 40 pi of ice cold 0.7 M NaOH and 15% zinc sidfate water solution. 
Precipitate was removed by centrifugation at 12,000 rpm. From each sample 200 yl 
supernatant were taken and mixed with 100 pi of color reagent (92 pi 
acetylacetone in 10 ml of 6.6 M ammonium acetate) quantification was 
accompalished at 405 nm in microplate reader. 
3.2.4. Determination of protein ketoamine in glycated HSA 
The glycation of HSA was quantified by a published colorimetric procedure using 
NBT (Mashiba et al., 1992) with shght modification. BSA (10 mg/ml) was 
incubated with 500 mM glucose for 15 days at imder sterile conditions 37°C in 20 
mM phosphate buffer pH 7.2 which results in modification of protein with 
subsequent formation of ketoamines. Native and glycated HSA samples (50 pi) 
were added to the wells of the 96-well microliters plates in duplicate. One 
hundred microUtres of NBT reagent (250 pi in 100 mM carbonate buffer, pH 10.3) 
was added to each well and incubated in dark at 37°C for 2 hours. The plate was 
read in a microplate reader at 550 nm and amoxmt of glycated HSA was calculated 
using the standard curve constructed with glycated BSA. 
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3.2,5. Assay of RNase A 
RNase A activity was determined spectrophotometrically vising yeast RNA as 
substrate. The standard reaction mixtiure in a total voliune of 2.5 ml contained 2 
mg of RNA and appropriate amovmt of RNase A in 0.1 M sodivrai acetate buffer, 
pH 5.0. The reaction was arrested after 10 minute incubation at 37 °C by using 
stopping reagent (22 M lanthanum chloride in IM perchloric acid), the reaction 
mixture was left on ice for 10 min and the precipitate formed removed by 
centrifiigation. Subsequently 0.2 ml of the supernatant was diluted with distilled 
water and the absorption of acid soluble ribonucleotides measiured at 260imi 
(Bergmeyer, 1984) 
3.2.5.1. Effect of temperature 
Both soluble and immobilized RNase A preparations were preincubated for 10 min 
at various temperatures ranging between 37-80'C in 0.1 M sodium acetate buffer, 
pH 5.0. The reaction was initiated by the addition of RNA followed by incubation 
at each temperature for 5 min and arrested by the addition of stopping reagent (22 
M lanthanum chloride in IM perchloric acid). 
3.2.5.2. Effect of pH 
To 250 (il of RNA (8 mg/ml) in 0.1 M NaH2P04 were added increasing volume of 
0.5 M NaOH and the volume made up to 450 pi with water. The volume of 0.5 M 
NaOH was increased in such a manner that the resiilting pH of the solution ranged 
from 5-10. The reaction was initiated by adding 50 pi of RNase A (1.1 imits) in 
distilled water followed by incubation at 37 °C for 5 min. The reaction was 
terminated by 500 |il of stopping reagent. The mixture was left on ice for 10 min 
and precipitate removed by centrifiigation (5000 x g, 10 min). Subsequently, 0.2 
ml of supernatant was diluted with 0.8 ml distilled water and the absorbance of 
the acid soluble nucleotides measvired at 260 nm. Similarly, the effect of pH on the 
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activity of RNase bo\ind to CNBr activated Sepharose was studied vising 50 |il of 
the immobilized RNase A preparations (activity wise similar) instead of soluble 
RNase A. 
3.3. Spectral Analysis 
3.3.1. UV absorption spectroscopy 
The UV absorption spectroscopy of native and sugar treated samples were 
obtained by measuring the absorption between 200 - 400 nm in a Shimadzu 
spectrophotometer using a cuvette of 1 cm pathlength. Three hundred micrograms 
of the samples in a total volvmie of 1 ml were taken for spectral analysis. 
3.2.2. Flourescence spectroscopy 
Samples (100 fig protein/ml) were analyzed by measuring intrinsic fluorescence at 
25±0.2''C in a Hitachi F2000 spectrofluorometer (Tokyo, Japan). The samples were 
excited at 285 nm and emission range was taken at 310-460 nm. Fluorescence 
measiurements were also made at 370 nm excitation and an emission range of 400-
500 nm. Appropriate controls containing the substances used for the treatment 
were run and corrections were made wherever necessary. 
3.2.3. Circular Dichroism 
All the Circular Dichroism (CD) measurements were carried out at 25°C on a Jasco 
spectropolarimeter Model J-720 using a SEKONIC XY Plotter (Model SP1-430A), 
with a thermostatically controlled cell holder attached to a NESLAB water bath 
Model RTE 110 with an accuracy of ±0.10 °C. The instrument was equipped with 
a microcomputer and recalibrated with (+)-10-camphersulfonic acid. The 
spectrum was recorded with a scan speed of 20 nm/ min and with a response time 
of 20 nm/min. Each spectrum was recorded as an average of two scans. Far-UV CD 
spectra were taken at a protein concentration of 20 |iM with a 1 and 10 mm path 
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length cells, respectively. CD spectra were recorded in the wavelength ranges of 
190-250 nm for far-UV. 
3.4 Immunological methods 
3.4.1. Immunization of rabbits 
Male rabbits weighing 2.2 kg were subcutaneously injected with 150 |ig of RNase 
A in 0.5 ml of 20mM phosphate bviffer mixed (1:1) with Freund's complete 
adjuvant. The animals were rested for 15 days and booster doses, prepared by 
mixing 100 ^g of RNase A/0.5 ml solution with equal volvunes of Freimd's 
incomplete adjuvant, were subcutaneously given at weekly intervals for 4 weeks. 
Blood was withdrawn through an ear vein and clot formation allowed to take 
place at room temperature for 6 hrs. Serum was collected by centrifugation and 
stored at 0°C. 
3.4.2. Ouchterlony double diflusion 
The procedure was described by Ouchterlony (1949) was used. Agar plates were 
prepared by pouring 25.0 ml of 1% (w/v) agarose solution in normal saline. The gel 
was allowed to soUdify and wells pimched. RNase A (about 30 jig) was loaded in 
the central well and 5-20 |il of adequately diluted antisera were added in the 
peripheral wells. The antigen was loaded after 4 hours at room temperature and 
subsequentiy overnight in a refrigerator. 
3.4.3. Direct binding enzyme-linked immunosorbent assay (ELISA) 
The titre of antigen specific antibodies was measured in the sera of immunized 
rabbits by ELISA. The 96 well microtitre plates (immimol 2HB, dynex, USA) were 
coated with 100 |il of RNase A at a concentration of 5 fig/ml in 0.05 M carbonate-
bicarbonate buffer, pH 9.6 for 2 hours at room temperature and then overnight at 
4°C. They were washed 3 times witii TBS-tween (0.14 M NaCl, 2.7mM KCl and 20 
mM Tris pH 7.4 with 500 fil/1 tween) to remove the unbound antigen. Unoccupied 
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sites were blocked with 150 |il of 1.5% (w/v) BSA in TBS for 3 hours at room 
temperature. The plates were washed with TBS-tween and serially diluted 
antiserum samples (100 |il/well) in TBS to be tested were added to each well 
(1:100—»^1:10,00,000). The plates were incubated for 2 hours at room temperature. 
After the usual washing steps, the peroxidase reaction was initiated by the 
addition of the substrate tetramethyl benzidine/ H2C)2, the reaction arrested by the 
addition of 4.0 N H2SO4 and absorbance at 450 nm measiured in an ELISA reader. 
Each sample was coated in dupUcate, and the results were expressed as mean of A 
test-A control. (A=absorbance at 450 nm). 
3.4.4. Isolation and purification of Immunoglobulin G 
IgG was isolated by a sUght modification of the method of Fahey and Terry (1979). 
Fifity ml of antisenun was mixed with equal voltune of 20 mM sodium phosphate 
buffer, pH 7.2 and 11.4 gms of solid ammoniimi stilphate was added. The mixture 
was stirred to dissolve ammonium sulphate and to make it 20% saturated. After 6 
hovirs the sample was centrifiiged at 2,000 x g for 20 minutes and the supernatant 
made 40% saturated with respect to ammonivun sulphate by adding additional 12.3 
gms of the soHd. Precipitation was allowed to proceed for 12 hours at 4°C. The 
precipitate obtained was collected by centrifugation at 2,000 x g for 20 minutes. 
Most of the gamma globulin was present only in the 20-40% pellet which was 
dissolved in minimvun voluine of 20 mM sodium phosphate buffer, pH 7.2 and 
extensively dialyzed against the same buffer with frequent changes and stored at 
4°C. 
Ten grams of DEAE-cellulose was suspended in 0.5 N HCl for one hour and 
washed in a Buechner fimnel with distilled water till the pH of the filterate was 
neutral. The exchanger was then treated with 0.5 N NaOH for 1 hour and again 
washed with distilled water till the pH of the filterate was neutral. DEAE-cellulose 
was then resuspended in 20 mM sodivun phosphate buffer, pH 7.2 to obtain 
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homogeneous slurry. Fine particles were removed by decantation and the slurry 
mixed with dialyzed ammonium svdphate fraction and stirred for 2 hours. The 
slurry was then centrifuged at 4,000 x g for 10 minutes to settle the particles and 
the supernatant thus obtained containing purified IgG was collected and analysed 
for the protein content. The homogeneity of purified protein was assessed by 
PAGE. 
3.5. Immobilization techniques 
3.5.1. Immobilizauon of antiKNase on cynogen bromide activated Sepharose 
The antiRNase IgG was coupled to activated Sepharose-4B (Porath et al, 1967). 
Briefly, 1.0 g Sepharose-4B was washed thoroughly with distilled water in a 
sintered glass funnel. The gel was sucked dry and suspended in 2.0 ml of distilled 
water and 1.0 ml of 2.0 M sodiiun bicarbonate (Na2CC)3). The slurry was stirred 
thoroughly at room temperature by placing it on a magnetic stirrer. Then 0.2 gm 
of cynogen bromide dissolved in 0.2 ml of acetonitrile was added to the beaker 
containing Sepharose gel and mixed thoroughly at 4°C for 15 minutes. The whole 
mass was then transferred to a glass sintered funnel and washed extensively with 
0.1 M bicarbonate bviffer, pH 8.5, distilled water and then with phosphate buffer. 
After thorough washings, the activated Sepharose was dried and suspended in 0.1 
M sodiimi bicarbonate buffer, pH 8.5. 
RNase A was immobilized on the antibody support by incubating 5500 units of the 
enzyme with 10 mg of Sepharose linked antiRNase in 0.1 M acetate buffer, pH 5.0 
for 12 h at 4°C. The matrix was separated from the unboimd enzyme by 
centrifugation and washed with the buffer. Amount of the enzyme immobilized 
were determined by subtracting from the amount of RNase added that present in 
the supernatant and washings by activity measurements. 
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3.5.2. Immobilization of RNase A on CNBr activated Sepharose 
Immobilization of RNase A was carried out by activating Sepharose 4B as 
described in the above section. RNase A (10 mg) was added to the activated 
Sepharose in O.IM sodium bicarbonate buffer pH 8.5 tinder stirring for 24 h at 
4°C. Amounts of the enzyme immobilized were determined by subtracting from 
the amount added those of the supernatant and washing by activity measurement. 
3.5.3. Immobilization of RNase A on CM-cellulose 
Ten grams of CM-cellvdose was suspended in 0.5 M NaOH for one hour and 
washed in a Buechner fuimel with distilled water till the pH of the filterate was 
neutral. The exchanger was then treated with 0.5 N HCl for 1 hovir and again 
washed Avith distilled water till the pH of the filterate was neutral. Ten mg of 
RNase A mixed with 1 g of regenerated CM-Cellulose was stirred at 4= C 
overnight. Amount of RNase A immobilized on support was calculated by 
subtracting the quantity of protein in the supernatant and washings from that 
added to the regenerated CM Cellulose. 
3.5.4. Effectiveness factor 
The effectiveness factor (T]) of the immobilized preparation represents the ratio of 
actual to theoretical catalytic activity of the immobilized enzyme (Jafri and 
Saleemuddin, 1997). Actual activity value of the enzyme was determined by 
assaying an appropriate aliquot of the immobilized preparation. Theoretical 
activities of enzyme preparations were calculated by subtracting the soluble 
enzyme vmits remaining (after immobilization) from that added for 
immobilization, T] value of an immobilized enzyme is a measxure of internal 
diffusion effect and reflects the efficiency of immobilization procedure in 
retaining the enzyme in active form. 
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3.6. Slab gel electrophoresis 
3.6.1. Polyacrylamide gel electrophoresis (PAGE) 
Electrophoresis was performed essentially according to the method of Laemmli 
(1970) tising the slab gel apparatus manufactured by Biotech, India. A stock 
solution of 30% acrylamide containing 0.8% bisacrylamide was mixed in 
appropriate proportion to give the desired percentage of gel. It was then poured 
into the mould formed by two glass plates (8.5 x 10 cm) separated by 1.5 mm thick 
spacers. Bubbles and leaks were avoided. A comb providing a template for seven 
wells was quickly inserted into the gel film and polymerization allowed to occur. 
After 15-20 minutes, the comb was removed and the wells were cleaned, overlaid 
with running buffer. Samples containing 15-35 |ag protein mixed with equal 
voliune of sample buffer (containing 10% (v/v) glycerol, 0.06 M tris HCl, pH 6.8 
and traces of bromophenol blue as tracking dye) were applied to the wells. 
Electrophoresis was performed at 100 V in the electrophoresis buffer containing 
0.025 M Tris and 0.2 glycine vmtil the tracking dye reached the bottom of the gel. 
3.6.2. Sodiimi dodecyl sulphate polyacrylamide gel electrophoresis (SDS - PAGE) 
Sodium dodecyl sulphate (SDS) PAGE was performed by the tris-glycine system of 
LaemmK (1970) using slab gel electrophoresis apparatus, manufactured by Biotech, 
India. Concentrated stock solution of 30% acrylamide containing 0.8% 
bisacrylamide, 1.0 M tris (pH 6.8 and 8.8) and 10% SDS were prepared and mixed 
in appropriate proportion to give the final required percentage. It was poured in 
the mould formed by two glass plates (8.5 x 10 cm) separated by 1.5 mm thick 
spacers avoiding leaks and bubbles. A comb providing a template for seven wells 
was quickly inserted into the gel before the polymerization began. The comb was 
removed once the polymerization was complete and wells were overlaid with the 
running buffer. Protein samples were prepared in the sample buffer containing 1% 
(w/v) SDS, 10% (v/v) glycerol, 0.0625 M tris HCl, pH 6.8 and traces of 
bromophenol blue as tracking dye along with 5% p-mercaptoethanol. The samples 
48 
were boiled at 100°C for five minutes. Electrophoresis was performed in 
electrophoresis buffer containing 0.025 M tris and 0.2 M glycine at 100 v till the 
tracking dye reached the bottom of the gel. 
3.7. Staining procedures 
After the electrophoresis was complete the gels were removed and the protein 
bands were visualized by staining. 
3.7.1. Coomassie brilliant blue staining 
Protein bands were detected by staining with 0.1% coomassie brilUant blue R-250 
in 40% isopropanol and 10% acetic acid. The staining was carried out with 10% 
glacial acetic acid. 
3.7.2. Silver nitrate staining 
The procedure described by Merril et al. (1982) was followed. After 
electrophoresis the protein bands were fixed by rapidly immersing in a mixture of 
40% (v/v) methanol and 10% (v/v) acetic acid for one hour with constant shaking. 
The gel was washed with 10% methanol and 5% (v/v) acetic acid twice, each time 
for 15 minutes to allow the gel to swell to normal size. This was followed by 
incubation in 3.4 mM potassiiun dichromate solution containing 3.2 mM nitric 
acid for 15 minutes and then thoroughly washed with distilled water. The washed 
gel was then immersed in 12 mM silver nitrate solution for 20 minutes and the 
again washed with distilled water and transferred to 280 mM solution of sodiimi 
carbonate containing 0.5% formaldehyde to make the gel alkaline. The reaction 
was stopped after 10 minutes by transferring the gel to 3% acetic acid solution for 
5 minutes. The gels were washed 4 to 5 times with distilled water and finally 
stored in distilled water. 
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4.0 RESULTS 
4.1 Studies on glycation of HSA 
HSA is the most abundant protein in plasma and comprises about 60 percent of the 
total proteins fovmd in blood plasma (Shaklai etal., 1984). In normal adults, nearly 
10 percent of the HSA is modified by glycation which increases 2-3 folds imder 
hyperglycemic conditions such as diabetes (Guthrow et al., 1979). As a result 
glycated albvmiin has been proposed as a useful marker for short term monitoring 
of diabetic patients and the levels of glycated albiunin might also be vised as an 
indicator of the degree of hyperglycemia (Nakajou et al., 2003). Glycation studies 
on HSA mainly focused on the reaction with glucose although some information 
with other sugars is also available. This part of thesis presents data on comparison 
of the effect of various sugars on HSA and the comparative protective effect of 
some compovmds/ drugs on glycation induced alterations in the molecule. 
4.1.1 Effect of incubation with reducing sugars on the properties of HSA 
4.1.1.1 SDS-PAGE 
HSA was incubated with glucose, finctose or ribose for 8 days and analyzed by 
SDS-PAGE in the presence of the thiol reductant p-mercaptoethanol, as detailed in 
the text. HSA not exposed to the sugars migrated as a single band but on 
incubation with the sugars, clear alterations in the electrophoretic behavior were 
evident. These included broadening of the protein band and decrease in the 
staining intensity. Two other effects notable in the SDS-PAGE are the presence of 
oligomeric population in samples treated with ribose and fructose suggesting the 
formation of aggregates (Fig. 10 B, C) and presence of faster migrating peptides 
(Fig. 10 A) in the glucose treated protein. As shown in Fig. 10 the alterations 
induced by ribose and fructose were more obvious than those induced by glucose. 
50 
Fig, 10. SDS-PAGE of HSA incubated with reducing sugars. HSA was incubated 
with 100 mM glucose (A), fructose (B) or ribose (C) separately upto 8 days in 20 
mM phosphate bviffer, pH 7.2 at ST'C and subjected to electrophoresis. Lanes 1 
contained HSA incubated without sugar, whereas Lanes 2-5 contained HSA 
incubated with sugars for 2, 4, 6 and 8 days respectively. Ten microgram of sample 
was loaded on each lane and subjected to SDS-PAGE in the presence of p-
mercaptoethanol. The gels were silver stained for visualization of protein bands. 
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4.1.1.2. Protein bound carbonyl groups 
HSA incubated with various sugars up to 8 days was analyzed for carbonyl content 
by reaction with DNPH (Fig. 11). The carbonyl content was considerably higher 
in the ribose treated sample followed by those treated with fructose and glucose. 
HSA incubated without sugar contained very small amoimt of carbonyl groups. 
Carbonyl content is considered a rehable indicator of glycation and is the most 
commonly used marker of protein oxidation and glycation, but the extent of 
carbonyl group formation varies from protein to protein, depending on the 
niunber and location of free amino groups present in the respective protein 
(Berlett and Stadtman, 1997; Beal, 2002). The relative reactivities of ribose, 
fructose and glucose in generating carbonyls substantiate the effects described in 
Fig. 10. The order of reactivity in the glycation reaction was ribose> ftuctose> 
glucose. 
4.1.1.3. Colorimetric determination of glycation 
Fig. 12 shows the progress of albumin glycation with the sugars, measured by 
borohydride-periodate assay. The amount of formaldehyde released at 405 nm was 
measured which is directiy proportional to the extent of glycation (Kennedy et al., 
1993). The observations were supported by analysis of the ketoamine moieties 
formed by glycation of HSA (Fig. 13). Ribose was most active in generating 
ketoamine groups on HSA followed by glucose. HSA not incubated with the sugar 
and that treated with fructose contains negligible ketoamine groups. The relative 
reactivities of sugars as evident from Fig. 10 & 11 however appeared different with 
fructose showing higher reactivity. Thus, while fructose was more reactive than 
glucose in inducing alterations in electrophoretic behavior as well as generation of 
protein bovmd carbonyl (Fig. 10 & 11), it was found less effective in liberating 
formaldehyde as well as inducing the formation of ketoamine groups. 
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Fig. 11. Carbonylation of HSA incubated with various reducing sugars. HSA was 
incubated with 100 mM glucose (A), fructose (X) or ribose (n) in 20 mM 
phosphate buffer, pH 7.2 up to 8 days. The samples were derivatized with DNPH 
and assayed for protein bound carbonyl groups. Control sample (O) was incubated 
mider identical conditions but without any sugar. Each value represent the meant 
S.D. for three experiments performed in duplicates. 
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Fig. 12. Effect of various sugars on borohydride reduction in periodate assay. HSA 
was incubated with 100 mM glucose (A), fructose (X) or ribose (n) in 20 mM 
phosphate buffer, pH 7.2 up to 8 days. The samples were treated with borohydride 
and periodate to measure the amount of formaldehyde released by glycated and 
unglycated HSA at 405 run. Control sample (O) was incubated tmder identical 
conditions but without any sugar. 
Fig. 13. Effect of various sugars on ketoamine formation in HSA. HSA was 
incubated with 100 mM glucose (A), fructose (X) or ribose (a) in 20 mM 
phosphate buffer, pH 7.2 up to 8 days. The samples were treated with NBT and 
assayed for protein boimd ketoamines. Control sample (O) was incubated under 
identical conditions but without any sugar. 
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4.1.1.4. Spectral properties of HSA 
It is well recognized that the reaction of reducing sugaTBasai=p?6?ein can cavise 
marked alterations in protein conformation. The glycation induced alterations in 
HSA were further examined with respect to their chromophoric and fluorophoric 
properties. Incubation with reducing sugars at 37°C for upto 8 days resulted in 
time dependent modification of HSA, as evident from the observed alterations in 
intrinsic fluorescence (Fig. 14), new fluorescence (Fig. 15) and absorbance at 280 
nm (Fig. 16). As shown in the figures, HSA incubated with the sugars revealed 
quenching in the intrinsic fluorescence, while a marked increase was observed in 
new fluorescence and absorbance at 280 nm. Several investigators have shown that 
reaction of sugars and aldehyde with proteins leads to the formation of groups like 
pentosidine which are considered characteristic biomarker of glycation and 
accompanying autoxidation. These adduct show strong emission between 400-500 
nm when excited at a wavelength of 370 nm (Schmidt, 1990; Traverse etal, 1997). 
To evaluate the changes in the secondary structure, the CD spectra in the range of 
190- 250 nm were measured for the control and samples treated with glucose, 
fructose or ribose for 8 days. The spectrum of HSA revealed two minima, one at 
208 nm and the other at 222 nm, which are indicative of the helical content of the 
protein (Fig. 17). It is evident that incubation with sugars lead to marked 
alterations in secondary structure. Glucose causes very little change in the 
secondary structure while maximum alteration was observed with ribose. 
4.1.1.5. Effect of various compounds on glycation with fructose 
Glycation reactions mediated by fructose (fructation) gained interest for variety of 
reasons. In tissues such as eyes and peripheral nerves polyol pathway is active and 
the concentration of fructose reaches that of glucose. The resultant fructose is 
known to be a strong glycating agent due the presence of high concentrations of 
the reactive open chain structures that react with protein amino groups at the rate 
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Fig. 14 A. Effect of incubation with various su^rs on tryptophan fluorescence of 
HSA. HSA was incubated in the absence (O) or presence of 100 mM glucose (A), 
fructose (X) or ribose (n) in 20 mM phosphate buffer, pH 7.2 for upto 8 days at 
37°C. Aliquots were withdrawn at 0, 2, 4, 6 and 8 days and dialyzed. Equivalent 
quantities of protein were withdrawn and the quenching was measured with 
respect to the HSA not incubated with either sugar. 
Fig. 14 B. Tryptophan fluorescence spectra of HSA incubated with various sugars. 
HSA was incubated in the absence (O) or presence of 100 mM glucose (A), 
fructose (X) or ribose (D) in 20 mM phosphate buffer, pH 7.2 for 8 days at 37°C. 
Samples were dialyzed prior to fluorescence measurement. The spectra were taken 
after excitation at 280 nm and emission range 300-400 nm. 
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Fig. 15 A. Effect of incubation with various sugars on new fluorescence of HSA. 
HSA was incubated in the absence (O) or presence of 100 mM glucose (A), 
fructose (K) or ribose (n) in 20 mM phosphate buffer, pH 7.2 for upto 8 days at 
37°C. Aliquots were withdrawn at 0, 2, 4, 6 and 8 days and dialyzed. Equivalent 
quantities of protein were withdrawn and the new fluorescence was measured 
with respect to the HSA not incubated with either sugar. 
Fig. 15 B. New fluorescence spectra of HSA incubated with various sugars. HSA 
was incubated in the absence (O) or presence of 100 mM glucose (A), fructose (X) 
or ribose (D) in 20 mM phosphate buffer, pH 7.2 for 8 days at 37°C. Samples were 
dialysed prior to fluorescence measurement. The spectra were taken after 
excitation at 370 nm and emission range 400-500 nm. 
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Fig. 16 A. Effect of incubation with various sugars on hyperchromicity of HSA. 
HSA was incubated in the absence (O) or presence of 100 mM glucose (A), 
fructose (X) or ribose (n) in 20 mM phosphate buffer, pH 7.2 for upto 8 days at 
37°C. AHquots were withdrawn at 0, 2, 4, 6 and 8 days and dialyzed. Equivalent 
quantities of protein were withdrawn and the absorbance at 280 nm v^^s measured 
with respect to the HSA not incubated with either sugar. 
Fig. 16 B. Absorption spectra of HSA incubated with various sugars. HSA was 
incubated in the absence (O) or presence of 100 mM glucose (A), fructose (X) or 
ribose (D) in 20 mM phosphate buffer, pH 7.2 for 8 days at 37°C. Samples were 
dialysed prior to measurement of absorbance at 280 nm. 
58 
B 
2 4 6 
Incubation tkne (days) 
8 
250 300 
Wavelength (nm) 
Fig. 17. Far UV CD spectra of HSA incubated with various sugars. HSA was 
incubated in the absence (—) or presence of 100 mM solutions of glucose ( ), 
fructose (- • -) or ribose (- •• -) in 20 mM phosphate buffer, pH 7.2 for 8 days at 
37°C. Samples were dialyzed prior to the CD measurement. 
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approx 10-folds higher as compared to that of glucose (Bunn and Higgins.1981). 
Fructose-mediated glycation and the protection provided by various compounds/ 
drugs were therefore investigated. The protective effect of some metal ion 
chelators, antioxidants, analgesics and other drugs have been investigated by 
measxiring increase in new fluorescence, quenching of tryptophan fluorescence 
and absorbance at 280 nm (Fig. 18). Each bar represents the percent change of the 
control resulting from the inclusion of specific compovmd. The result obtained 
showed that DETAPAC, EDTA and aminoguanidine have strong protective effect 
while aspirin, ibuprofen, paracetamol and pencillamine exert only moderate 
protection. Ascorbic acid showed only marginal protective effect. 
For further characterization of the protection provided by the compounds, HSA 
samples incubated with fructose and inhibitors were subjected to SDS-PAGE. The 
fructose treated samples showed characteristic variation already shown in Fig. 10, 
while the HSA samples incubated with various compoimds along with fructose 
showed varying degrees of decrease in sugar-induced alterations in electrophoretic 
behavior. Aminoguanidine, EDTA, paracetamol were more effective compared to 
other compounds in this regard (Fig. 19, 20) 
Fig. 21 showed SDS-PAGE of HSA incubated with fructose along with Cu^ * ions in 
the absence or presence of DETAPAC. The metal ions were fovmd to markedly 
enhance the fragmentation of HSA as revealed by the disappearance of the protein 
band while some aggregated material remained at the top of the gel. DETAPAC 
was remarkably effective in reducing the combined effect of sugar and Cu^ * ions. 
4.1.1.6. Effect of some flavonoids on glycation with fructose 
The protection against fructose-mediated HSA glycation by flavonoids was 
determined by electrophoresis (Fig. 22) and alterations in spectral parameters (Fig. 
23). The residt showed that sorae ^axonoids were quite e^ectxve in restricting the 
sugar induced alterations in the electrophoretic behavior of HSA. Quercetin and 
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Fig. 18. Protective e£fect of various compovmds/ drugs on fructose-induced 
alterations in HSA, HSA was incubated with 100 mM fructose for 8 days in the 
presence of various compounds at a concentration of 25 rtiM. Incubated samples 
were dialyzed and equal quantities of protein were taken for new fluorescence 
(A), tryptophan fluorescence (B) and hyperchromicity (C). Relative values were 
calculated taking the value of HSA incubated without fructose as 100. All the 
values are meant S.D for three experiments performed in dupUcates. 
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Fig. 19. SDS-PAGE of HSA incubated with fructose in the presence of some 
inhibitors of glycation. HSA was incubated with 100 mM fructose in 20 mM 
phosphate buffer, pH 7.2 at 37°C for 8 days in the absence or presence of various 
compounds/ drugs at a concentration of 25 mM. Lane 1 contained HSA; Lane 2 
contained HSA incubated with fructose; Lanes 3, 4, 5 and 6 contained HSA 
incubated with fructose along with EDTA, ibuprofen, pencillamine and ascorbic 
acid respectively. 
Fig. 20. SDS-PAGE of HSA incubated with fructose in the presence of some 
inhibitors of glycation. HSA was incubated with 100 mM fructose in 20 mM 
phosphate buffer, pH 7.2 at 37°C for 8 days in the absence or presence of various 
compounds/ drugs at a concentration of 25 mM. Lane 1 contained HSA; Lane 2 
contained HSA incubated with fructose; Lanes 3, 4 and 5 contained HSA 
incubated with fructose along with paracetamol, aminoguanidine and aspirin 
respectively. 
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Fig. 21, SDS-PAGE of HSA incubated with fructose along with metal ions in the 
presence of DETAPAC. HSA was incubated with 100 mM fructose in 20 mM 
phosphate buffer, pH 7.2 at 37°C for 8 days in the presence of 0.1 mM Cu^ * ions. 
Lane 1 contained HSA; Lane 2 contained HSA incubated with fructose; Lane 3 
contained HSA incubated with fructose and Cu^ * ions, Lane 4 contained HSA 
incubated with fructose and DETAPAC and lane 5 contained HSA incubated with 
fructose Cu^ * ions and DETAPAC respectively. 
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Fig. 23. SDS-PAGE of HSA incubated with fructose in the presence of some 
flavonoids. HSA was incubated with 100 mM fructose in 20mM phosphate buffer, 
pH 7.2 at 37°C for 8 days in the absence or presence of flavonoids at a 
concentration of 10 fiM. Lane 1 contained HSA; Lane 2 contained HSA incubated 
with fructose; Lanes 3, 4, 5, 6, and 7 contained HSA incubated with fructose along 
with quercetin, rutin, naringin, myricetin and catechin respectively. 
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rutin were more protective compared to naringin and myricetin, while catechin 
was not protective. New fluorescence, tryptophan fluorescence and 
hyperchromicity also suggest the protective effect of flavonoids to be in the order 
rutin> quercetin> naringin> myricetin> catechin. 
4.2 Studies on RNase A 
4.2.1. Effect of reducing sugars on RNase A 
EarUer studies have shown that RNase A incubated with sugars undergoes 
structural modification and loss in catalytic activity like several other enzymes 
(Seidler, 2005). Use of RNase A therefore offers catalytic activity measurement as 
an additional parameter of glycation reaction. It is also well recognized that the 
enzyme is highly stable against various forms of inactivation. As shown in Fig. 24, 
glucose, finctose and ribose cause marked inactivation of RNase at 37° C, but the 
loss of catalytic activity was most rapid in the presence of ribose. Incubation with 
glucose, fructose or ribose resulted in loss of 36, 62 and 84 percent activity 
respectively after 8 days incubation at 37" C. RNase did not lose significant activity 
when incubated in absence of the sugars for upto eight days. 
Fig. 25 illustrates SDS-PAGE of RNase exposed to the sugars revealed broadening 
of the RNase band, decrease in staining intensity as well as appearance of 
additional large and small molecular weight bands. The loss of band intensity also 
appeared maximum with ribose followed by fructose and ribose. 
4.2.2 Effect of incubation with sugars on spectral properties of RNase A 
The sugar induced alterations on RNase were also examined with respect to their 
chromophoric and fluorophoric properties. As shown in Fig. 26, a marked increase 
in new fluorescence was also observed with the sugars following the anticipated 
order i.e. ribose > fiiictose >glucose. 
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Fig. 24. Effect of reducing sugars on the activity of RNase A. RNase A (1 mg/ ml) 
was incubated with 100 mM glucose (A), fructose (x) or ribose (D) separately for 
2, 4, 6 and 8 days in 20 mM phosphate buffer, pH 7.2 under sterile conditions at 
SyC. Control sample contained RNase A (•) not incubated with any sugar up to 8 
days. Aliquots were removed at appropriate intervals and the enzyme activity 
measured under standard assay conditions. Each value represents the average for 
three independent experiments performed in duplicate. 
Fig. 25. SDS-PAGE of RNase A incubated with reducing sugars. RNase A was 
incubated with 100 mM glucose, fructose or ribose separately for upto 8 days in 20 
mM phosphate buffer, pH 7.2 at 37°C and subjected to electrophoresis. Lanes 1 
contained RNase A incubated in the absence of sugar whereas Lanes 2-4 contained 
RNase A incubated Avith glucose, fructose or ribose respectively. Ten microgram 
of sample was loaded on each lane and the gels were silver stained for 
visualization of protein bands. 
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Fig. 26. Effect of sugars on the spectral properties of RNase A. RNase A (Img/ml) 
was incubated with 100 mM glucose (X), fructose (n) or ribose (A) separately at 
37°C for 8 days. Control sample contained RNase A (O) not incubated with any 
sugar up to 8 days.Samples were dialyzed for the analysis of new fluorescence (A), 
tyrosine fluorescence (B) and hyperchromicity (C). RNase A incubated without 
sugar (o) under similar conditions were taken as control. 
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Quenching of tyrosine fluorescence of RNase A was also measured as an additional 
index of alteration in structure/conformation. As observed with new fluorescence 
the magnitude of quenching also varied markedly and maximum quenching was 
observed in case of ribose-treated RNase, while enzyme treated with glucose 
revealed minimvmi quenching. 
The UV spectra of RNase incubated with the sugars exhibited marked increase in 
absorbance at 280 nm as compared to the control sample incubated in the absence 
of sugar. However the magnitude of hyperchromicity induced by sugars varied 
markedly and among various sugars studied, maximvun h):perchromicity was 
observed in ribose-treated RNase followed by that incubated with fructose and 
glucose. 
Fig. 27 depicts the far UV-CD spectra between 200-250 run of control and the 
sugar treated RNase A incubated for 8 days at 37°C. As can be seen from the figure 
a remarkable change in the spectrum of RNase A incubated in the presence of 
sugar was observed. Inclusion of ribose in the reaction mixture resulted in 
maximvun alterations suggestive of marked loss of secondary structure. 
4.2.3. Effect of various compounds on the fructose induced alterations in RNase A 
The protective effect of some metal ion chelators, antioxidants, analgesics and 
other drugs that have been shown to interfere with glycation has been 
investigated. The protective effect of the compovmds was assayed using various 
parameters such as effect on enzyme activity (Fig. 28 A), hyperchromicity (Fig. 28 
B), generation of new florescence (Fig. 29 A) as well as quenching of tyrosine 
fluorescence (Fig. 29 B). Each bar represents the percent inhibition of glycation as 
compared to control. SDS-PAGE of RNase A incubated with fructose along with 
the compovmds also revealed decrease in cross-linking as compared to RNase A 
incubated with fructose alone (Fig. 30). Among the compounds investigated 
aminoguanidine, DETAPAC and EDTA were found to be most protective, while 
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Fig. 27. Far UV OD spectra of RNase A incubated with various sugars. RNase A 
was incubated in the absence (—) or presence of 0.5 M solutions of glucose ( ), 
fructose (- • -) or ribose ( ) for 8 days at 37°C. Samples were dialyzed prior to 
the CD measvurement. 
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Fig. 28. Protective effect of varioxis compoxinds/ drugs on fructose-induced 
alterations in RNase A. RNase A was incubated with 100 mM fructose for 8 days 
in the presence of various compounds at a concentration of 25 mM. Incubated 
samples were dialyzed and equivalent quantities of protein were taken for enzyme 
activity (A) and hyperchromicity (B). Percent remaining activity and 
hyperchromicity was calcvdated taking the value of sample incubated without 
sugar as 100. All values are mean ± S.D for three experiments performed in 
duplicates. 
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Fig. 29. Protective effect of various compoimds/ drugs on fructose-induced 
alterations in RNase A. RNase A was incubated with 100 mM fructose for 8 days 
in the presence of various compounds at a concentration of 25 mM. Incubated 
samples were dialyzed and equivalent quantities of protein were taken for new 
fluorescence (A) and tyrosine fluorescence (B). Increase in new fluorescence and 
quenching in tyrosine fluorescence was calculated taking the value of sample 
incubated without sugar as 100. All values are mean ± S.D for three experiments 
performed in duplicates. 
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Fig. 30. SDS-PAGE of RNase A incubated with fructose in the presence of various 
compoimds/ drugs. RNase A was incubated with 100 mM fructose in 20 mM 
phosphate buffer, pH 7.2 at 37°C for 8 days in the absence or presence of various 
compounds/ drugs at a concentration of 25 mM. Lane 1 contained RNase; Lane 2 
contained RNase A incubated with fructose; Lanes 3, 4, 5, 6, 7, 8, 9 and 10 
contained RNase A incubated with fructose and EDTA, DETAPAC, 
aminoguanidine, paracetamol, ibuprofen, aspirin, penciUamine and ascorbic acid 
respectively. 
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pencillamine, aspirin and iburofen were moderatly protective. Ascorbic acid was 
found to lower the quenching of intrinsic fluorescence as well as generation of 
new fluorescence to a certain extent but it neither reduced the cross-linking of 
RNase A nor provided significant protection against enzyme inactivation. 
4.2.4 Effect of flavonoids on the fructose induced alterations in RNase A 
The inhibition of fructose-mediated RNase A glycation by various flavonoids was 
also investigated by SDS~PAGE (Fig. 31), effect on enzyme activity (Fig. 32 A) and 
hyperchromicity (Fig. 32 B), generation of new fluorescence (Fig. 33 A) quenching 
of tyrosine fluorescence (Fig. 33 B). Fructose readily reacts with RNase A to 
produce high molecular weight aggregates as revealed by SDS-PAGE. As shown in 
the Fig. 31, RNase A incubated with fructose migrated as diffuse band as compared 
to native enzyme. Some flavonoids, especially rutin and quercetin protected RNase 
A against inactivation as well as formation of high molecular weight aggregates. 
The protective effect of naringin and myricetin were however moderate while 
catechin showed no significant inhibitory effect. Investigation of new fluorescence 
also supported the protective effect of rutin and quercetin but not catechin. 
4.3. Evaluation of immobilized RNase A based assay for glycation 
Taking under consideration, the potential of using loss of RNase A activity as 
parameter for screening of glycation inhibitors the possibility of using 
immobilized RNase A with enhanced stabihty and easy separability from the 
reaction mixture was investigated. For this piirpose RNase A immobilized on 
CNBr activated Sepharose is used. 
4.3.1 Stabihty studies of immobilized RNase A 
4.3.1.1. Effect of temperature 
The temperature activity profile of soluble and immobilized RNase A preparations 
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Fig. 31. SDS-PAGE of RNase A incubated with fructose in the presence of 
flavonoids. RNase A was incubated with 100 mM fructose 20 mM phosphate 
buffer, pH 7.2 at 37°C for 8 days in the absence or presence of flavonoids at a 
concentration of 10 |iM. Lane 1 contained RNase A; Lane 2 contained RNase A 
incubated with fructose; Lanes 3, 4, 5, 6 and 7 contained RNase A incubated with 
fructose and rutin, quercetin, naringin, myricetin and catechin respectively. 
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Fig 32. Protective effect of flavonoids on fructose-induced alterations in KNase A. 
RNase A was incubated with 100 mM fructose for 8 days at 37°C in the presence 
of various flavonoids at a concentration of 10 jiM. The samples were dialyzed and 
equal quantities of protein were taken for increase in enzyme activity (A), and 
hyperchromicity (B). Relative values were calculated taking the value of sample 
incubated without sugar as 100. All values are mean ± S.D for three experiments 
performed in duplicates. 
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Fig 33. Protective effect of flavonoids on fructose-induced alterations in RNase A. 
RNase A was incubated with 100 mM fructose for 8 days at 37°C in the presence 
of various flavonoids at a concentration of 10 |iM. The samples were dialyzed and 
equal quantities of protein were taken for increase in new fluorescence (A) and 
quenching of tyrosine fluorescence (B) Relative values were calculated taking the 
value of sample incubated without sugar as 100. All values are mean ± S.D for 
three experiments performed in duplicates. 
77 
B 
jJJ 
J^ 
^ 
^^ 
0) 
w 
o 
^* 
O) 
£ o c 
3 
O 
100 
80 j 
60 i 
40 
20 J 
0 
.O^ 
^N '^ 
1 
j 
t 
J 
[ 
1 
-Tfr 
fTil?: 
r*Ti : 
: 
" ^ T l 
x>>- .J?'' <^ je>' j ^ ' 
Oiesulis 
are shown in Fig. 34. While the immobilization did not alter the optimimi 
temperature (60°C) of RNase A, the immobilized preparation retained a far greater 
fraction of activity at higher temperature as compared to the soluble enzyme. At 
70°C, RNase A immobilized on Sepharose supports retained over 85% of initial 
activity while the soluble enzyme retained less than 70%. The immobilized 
preparations also appeared significantly more stable at 80°C. 
4.3.1.2. Effect of pH 
The pH activity profile of soluble and immobilized RNase A preparations are 
shown in Fig. 35. Immobilization on Sepharose support did not alter the optimum 
pH (pH 8.0) of the enzyme. The immobilized preparation however showed the 
moderate broadening of the pH-activity profile and retained greated fraction of 
activity both in acidic and alkaline range as compared to the soluble enzyme. 
4.3.2. Effect of incubation with sugars on RNase activity 
As has been reported earlier (Raines, 1998) bovine pancreatic RNase was 
thermostable and retained nearly complete enzyme activity after incubation at 
60°C for two days (Fig. 36). Extension of the dvuration of incubation to foxu: days 
resulted only in a loss of about 10 percent enzyme activity. Incubation of RNase 
with reducing sugars at 60°C however resiilted in rapid inactivation of the 
enzyme. Among the sugars investigated, ribose was most active causing the loss of 
about 80 percent RNase activity in two days and the enzyme inactivation 
increased to 90 percent after four days of incubation. Glucose and fructose also 
inactivated RNase but to a smaller extent and a two day incubation at 60°C 
resulted in 20 and 60 percent loss of the enzyme activity respectively. RNase 
coupled to the CNBr-activated Sepharose was also susceptible to inhibition by the 
reducing sugars at 60°C and the pattern of inhibition resulting from the incubation 
with sugars with immobihzed RNase was comparable with that observed with the 
soluble enzyme. 
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Fig. 34. Effect of temperature on the activity of soluble and immobilized RNase A. 
Appropriate quantities of soluble and immobilized RNase A preparation were 
incubated with 2 mg of RNA in a total voltune of 0.5 ml at the indicated 
temperatures for 5 min in 0.1 M sodiimi acetate buffer, pH 5.0. The preparation of 
RNase A investigated were: soluble (A) and immobilized on Sepharose-4B (D). 
Each point represents the mean of three ejqieriments. 
Fig. 35. Effect of pH on the activity of soluble and immobilized RNase A. 
Activity of soluble and immobilized RNase A preparation were determined 
between pH 5-10 as described in the methods section , 3.2.5.2. The preparation of 
RNase A investigated were: soluble (A) and immobiUzed on Sepharose-4B 
(a).Each point represents the mean of three experiments 
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Fig, 36. Effect of reducing sugars on the activity of soluble (A) and immobilized 
(B) RNase A. RNase was incubated with either 500 mM glucose (•), fructose (A), 
ribose (•) for upto 4 days under sterile conditions at 60°C. AJiquots were removed 
at appropriate intervals and the enzyme activity was measured vmder standard 
assay conditions. Control sample contained RNase (X) not incubated with any 
sugar up to 8 days. Each value represents the average for three independent 
experiments performed in duplicate. 
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4.3.3. Effect of incubation with sugars at 60 "C in the spectral properties of 
RNaseA 
It is now well recognized that reaction of reducing sugars with protein can cause 
marked alterations in protein conformation (Ahmad, 2005). Incubation with 
reducing sugars at 60°C resulted in modification of soluble RNase A as evident 
from the observed alteration in intrinsic fluorescence (Fig. 37), new fluorescence 
(Fig. 38) and absorbance at 280 nm (Fig. 39). As shown in the figure RNase A 
incubated with the reducing sugars revealed a marked increase in new 
fluorescence and absorbance at 280 nm, while the quenching was observed in the 
intrinsic tyrosine fluorescence. The pattern of inhibition resulting from the 
incubation with sugars with immobilized RNase A was comparable with that 
observed with the soluble enzyme incubated with sugars for upto 8 days at 37°C. 
Clearly, ribose was most reactive in causing alterations followed by fructose and 
glucose. Quenching in the tyrosine fluorescence is attributed to the exposvue of 
the phenoUc groups to a less hydrophobic environment (Shaklai et al., 1984). 
Similarly increase in absorbance at 280 nm is attributed to protein unfolding and 
exposure of the chromophoric groups (Traverso etal., 1997). 
Fig. 40 depicts the far UV-CD spectra of control and ribose treated RNase A 
incubated for 1, 2 and 4 days at 60°C between 205-250 nm. As can be seen from 
the figure, no remarkable change in the spectrum of RNase A incubated in the 
absence of sugar was observed while inclusion of ribose in the reaction mixture 
resulted in a time dependent alterations suggestive of marked loss of secondary 
structvue. Seidler (2005) suggested that changes in secondary structure could lead 
to locahzed compaction of the protein. 
4.3.4. SDS-PAGE of RNase A incubated with sugars 
RNase A exposed to the various reducing sugars at 60°C was subjected to SDS-
PAGE in presence of the thiol reductant p-mercaptoethanol. Fig. 41 showed that 
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Fig. 37. Tyrosine fluorescence spectra of RNase A. RNase A was incubated in the 
absence (o) or presence of 500 mM solutions of glucose (x), fructose (D) or ribose 
(A) for 2 days at 60°C. Samples were dialyzed prior to fluorescence measurement. 
The spectra were taken after excitation at 290 nm. Fresh RNase A (•) not 
incubated with either sugar was also taken along with RNase incubated at 60°C for 
2 days. 
Fig. 38. New fluorescence spectra of RNase A. RNase A was incubated in the 
absence (o) or presence of 500 mM solutions of glucose (x), fructose (a) or ribose 
(A) for 2 days at 60°C. Samples were dialyzed prior to fluorescence measurement. 
The spectra were taken after excitation at 370 nm. Fresh RNase A (•) not 
incubated with either sugar was also taken along with RNase incubated at 60°C for 
2 days 
Fig. 39. Absorption spectra at 280 nm of RNase A. RNase A was incubated in the 
absence (o) or presence of 500 mM solutions of glucose (x), fructose (n) or ribose 
(A) for 2 days at 60°C. Samples were dialysed prior to fluorescence measurement. 
The spectra were taken between 250-300 nm. Fresh RNase A (•) not incubated 
with either sugar was also taken along with RNase incubated at 60°C for 2 days. 
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Fig. 40. Far UV CD spectra of RNase A incubated with ribose. RNase A was 
incubated in the absence (A) or presence of 500 mM solutions of ribose (B) for 1, 2 
and 4 days at 60°C. Samples were dialyzed prior to CD measurement and 250 ]A of 
sample was used for the analysis. 
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Fig, 41. SDS-PAGE of RNase A incubated with various sugars. RNase A was 
incubated with 500 mM glucose, fructose or ribose in 20 mM phosphate buffer pH 
7.2 at 60°C for two days luider sterile conditions and subjected to electrophoresis. 
Lane 1 contained RNase A incubated in the absence of sugar; Lane 2-4 contained 
RNase A incubated with glucose, fructose and ribose respectively. 
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incubation of RNase with the reducing sugars resulted in marked broadening of 
the bands and/or decrease in electrophoretic mobility suggesting non disulphide 
crosslinking. The alteration in electrophoretic behavior was most prominent in the 
RNase incubated with ribose followed by those with fructose and glucose. 
4.3.5. Effect of some glycation inhibitors 
4.3.5.1. Effect of chemical compounds 
The protective effect of some metal ion chelators, antioxidants, analgesics and 
other drugs that have been shown to interfere with glycation, on the activity of 
soluble and immobihzed RNase A incubated with ribose at 60°C was also 
investigated. DETAPAC was most effective in protecting the enzyme activity, 
followed by aminoguanidine, EDTA, pencillamine, aspirin and paracetamol. 
Ascorbic acid and ibuprofen were less inhibitory. As evident from Fig. 42, a good 
correlation was observed between the extents of protection provided by several 
compoimds when either soluble or immobilized RNase A was used. An excellent 
agreement in the protection offered by DETAPAC, EDTA, aminoguanidine, 
paracetamol and ascorbic acid was observed when either soluble or immobilized 
RNase A was used. In case of aspirin and ibuprofen however the protection 
appeared more marked when the immobilized enzyme was used. The difference 
may be attributed to interference by the drugs in the assay of soluble RNase A. 
Since the activity of immobiUzed RNase A was measured after centrifugation and 
washing of the immobilized preparation, the possible interference by the drugs in 
the assay is apparently eliminated. Aspirin is known to act by acetylation of free 
amino groups of proteins (Swamy and Abraham, 1989) and hence may contribute 
additionally towards the inactivation of RNase A. While similar action can be 
envisaged in case of the immobilized enzyme, it is not unUkely that some of the 
crucial side chain amino groups are less accessible due to immobilization of the 
enzyme. 
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Fig. 42. Protective e£fect of varioxas compoimds/ drugs on activity of RNase A 
treated with ribose. RNase A was incubated with 500 mM ribose for 2 days at 60°C 
in the presence of plant extracts at a concentration of 25 mM. Activity of soluble 
(D) and immobilized RNase A (•) incubated in the absence of ribose was taken as 
100 for the calcvdation of percent remaining activity in various samples. All the 
values are mean± S.D for three experiments performed in dupHcates 
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4.3.5.2. Effect of some plant extracts 
Ability of some plant-derived tissue extracts to protect RNase A against 
inactivation induced by ribose was also measured at 60°C. As shown in Fig. 43, 
extracts of green tea, ginger, garlic, grape, tomato and bitter gourd were 
significantly protective against the inactivation of both soluble and immobilized 
RNase A. The observed protection by ginger and bitter govurd extract was 
comparable when either soluble or immobilized RNase A was employed. There 
was however observed variation in the magnitude of protection in case of the 
intensely colored extracts derived from tomato, grapes and turmeric and the 
extent of protection appeared more marked in case of the soluble enzyme. Thus, 
while incubation of soluble RNase A with green tea extract resulted in the 
retention of 34 percent of control activity that observed with immobiHzed enzyme 
was 70 percent. Similarly, the observed retention in the RNase A activity 
incubated with the extracts of grape, tomato and tiuineric extracts were 
respectively 33%, 31% and 42% while using soluble enzyme and 59%, 60%, and 
64% when immobiHzed enzyme preparation was used. 
4.3.5.3. Effect of some flavonoids 
Fig. 44 showed the protective effect of various flavonoids on glycation induced 
inactivation of soluble and immobilized RNase A by ribose at 60°C at a 
concentration of 10 |iM. The result indicated that quercetin and rutin showed 
maximvun protection followed by myricetin and naringin. However catechin 
exhibited a Uttle protection indicating that only some flavonoids are effective in 
the prevention of sugar induced alterations. There was however observed 
variation in the magnitude of protection in case of the intensely colored flavonoids 
such as quercetin and catechin and the extent of protection appeared more 
marked in case of the immobilized enzyme. 
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Fig. 43. Protective effect of some plant extracts on activity of RNase A treated 
with ribose. RNase A was incubated with 500 mM ribose for 2 days at 60°C in the 
presence of plant extracts at a concentration of 25 mM. Activity of soluble (D) and 
immobihzed RNase A (•) incubated in the absence of ribose was taken as 100 for 
the calculation of percent remaining activity in various samples. All the values are 
mean± S.D for three experiments performed in duphcates. 
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Fig. 44. Protective effect of various flavonoids on activity of RNase A treated with 
ribose. RNase A was incubated with 500 mM ribose for 2 days at 60''C in the 
presence of flavonoids at a concentration of 10 \JM. Activity of soluble (D) and 
immobilized RNase A (•) incubated in the absence of ribose was taken as 100 for 
the calculation of percent remaining activity in various samples. All the values are 
mean± S.D for three experiments performed in duplicates. 
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4.4. Use of antibody support for protection against glycation 
4.4.1. Immunization of rabbits and pvirification of IgG 
RNase A proved to be a good antigen, despite of its relatively small size. Fig. 45 
shows the results of Ouchterlony double diffusion and ELISA suggesting the 
presence of antiRNase antibodies in the sera of immtmized rabbits. The antiRNase 
IgG was purified to homogeneity on a protein A Sepharose column (Fig. 46) and 
the purity of the isolated IgG ascertained by SDS-AGE (Fig. 47 A). Two bands 
were visible on SDS-PAGE of IgG and their molecular weight as determined by 
the semilogarithmic plot of the molecular masses against the distance of migration 
correspond to those of heavy (50 kd) and light chain (25 kd) of IgG (Fig. 47 B). 
4.4.2. Immobilization of RNase A on immunoaffinity and CM cellulose supports 
The IgG isolated from the sera of rabbits immunized with the native RNase A 
when coupled to CNBr activated Sepharose were effective in binding RNase A 
from the solution. The RNase A also boimd effectively to CM-celltdose support at 
pH 7.2. As shown in the table 1, both the supp>orts used contain comparable 
quantities of bovmd RNase A, but the immobilized preparations differed with 
regard to the effectiveness factor (Iqbal & Saleemuddin, 1983). The T] values for 
RNase bound to antiRNase IgG and CM-cellulose support were 0.89 and 0.65. 
4.4.3. Effect of various sugars on soluble and immobilized preparation of RNase A 
The activity of soluble RNase A and that bound on to CM-cellulose dturing 
incubation with variovis sugars for eight days was markedly. As evident from Fig. 
48, the inactivation was maximum with ribose and minimum with glucose. The 
remaining activity of RNase A immobilized on the ion exchanger incubated for 
eight days was only moderately higher than that of soluble enzyme incubated 
imder the same conditions. Enzyme bound to the antibody support however 
retained markedly higher activity as compared to the soluble or CM-cellulose 
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Fig. 45. Detection of the antiRNase A antibodies in the antiserum. Ouchterlony 
double immunodiffusion (A) and ELISA (B) were performed to demonstrate the 
presence of antiRNase A antibodies. Details are given imder methods (section 
3.4.2 and 3.4.3) 
B 
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Fig. 46. Elution profile of antiRNase A IgG fix)m a Protein A-Sepharose column. 2 
ml of immvme serum was loaded on (5 x 1 cm) coliunn and washing performed 
with 0.1 M Tris/HCl buffer, pH 8.9. containing 3 M NaCl. The bound IgGs were 
eluted with 0.1 M glycine/HCl buffer, pH 3.0, and the eluate immediately 
neutralized with the 1 M Tris/HCl buffer, pH 8.9. Fractions of 0.5 ml were 
collected. 
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Fig. 47. SDS-PAGE of IgG and determination of molecular weight of the IgG. The 
IgG purified firom the sere of rabbits immxmized with RNase A using a Protein A-
Sepharose column was subjected to SDS-PAGE as described in the methods, 
section 3.3.9. Panel A Lane 1 contained 10[ig standard marker protein mixture; 
myosin (205 kd), phosphorylase b (97.4 kd), BSA (68 kd), ovalbumin (43 kd), 
carbonic anhydrase (29 kd), soyabean trypsin inhibitor (20 kd), lysozyme (14.3 kd) 
and aprotinin (6.5 kd). Lane 2 contained lOfig of antiRNase A IgG. Panel B shows 
the semi logarithmic plot of the molecvilar masses against the distance of 
migration of the standard marker proteins. Arrow 1 and 2 indicate the position of 
the small and large molecular weight peptides, respectively. 
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Table 1: Immobilization of RNase A on CNBr activated and antiRNase 
A coupled Sepharose supports. 
Support 
CM-cellulose 
AntiRNase A-Sepharose 
RNase A bound (U/ml) 
Theoretical 
(a) 
228.0 
232.0 
Actual 
(b) 
148.0 
208.0 
Effectiveness 
factor 
n(b/a) 
0.65 
0.89 
Each value represents the mean of three independent determinations. Maximum 
variation did not exceed ±5.5 units. 
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Fig. 48. Effect of incubation with sugars on the activity of soluble (D) and that 
botmd to CM-cellulose (QD) or antiRNase antibody support (H). RNase A was 
incubated with 500 mM either sugar for 8 days under sterile conditions at 37°C. 
The RNase A bound to CM-cellulose support or antibody support was eluted and 
enzyme activity measured. Activity of RNase A incubated in the absence of sugar 
was taken as 100. Each value represents the average for three independent 
experiments performed in dupUcate. 
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bound enzyme. The difference was most remarkable in samples incubated with 
ribose, with the enzyme retaining over 65 percent activity as compared to the 20 
and 30 percent activities respectively retained by soluble and CM-celluIose bound 
RNase A. 
4.4,4. SDS-PAGE of RNase A exposed to the sugar in soluble and immobilized state 
Fig. 49 shows the SDS-PAGE profiles of soluble RNase A incubated with the 
sugars as well as those of the enzyme exposed to the sugars while remaining bound 
to either CM-cellulose or the antibody support. The later were eluted and 
subjected to electrophoresis as described in the text. Soluble enzyme exposed to 
the sugars revealed marked broadening of the band, decrease in staining intensity 
as well as appearance of additional large and small moleoilar weight bands. In 
addition, staining observed at the top of the gel indicated the formation of very 
large molecular weight aggregates. The alterations were also more marked in 
samples incubated with ribose followed by fructose and glucose. RNase A 
immobilized on the antibody support was however clearly resistant to the sugar-
induced alterations and showed minimimi alteration in the electrophoretic 
behavior. 
4.4.5. Effect of immobilization on sugar induced alterations in the conformation of 
RNase A 
Spectroscopic studies of the soluble RNase A and that incubated with the sugars 
while remaining bound to the CM-cellulose or antibody Sepharose further 
revealed the protective role of the antibodies. Glucose induced a moderate 
increase in absorbance of the soluble enzyme and enzyme bound to CM-cellulose 
in eight days, while the alterations in the antibody bound RNase A preparation 
were minimal. The differences were more marked when the RNase A preparations 
were incubated with fructose or ribose. As evident from the Fig. 50, the 
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Fig. 49. SDS-PAGE of RNase A preparation incubated with reducing sugars. RNase 
A was incubated with 500 mM glucose (A), fructose (B) or ribose (C) separately up 
to 8 days in 20 mM phosphate bxiffer, pH 7.2 at Sy^ C^. Lane 1 contained RNase A 
incubated without any sugar. Lane 2 contained soluble RNase A, Lane 3 & 4 
contained RNase A exposed to the sugars while remaining bound to antiRNase A 
antibody or CM-cellulose support. 
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Fig. 50. Effect of various sugars on hyerchromicity of soluble RNase A (D), RNase 
A bound to antiRNase A Sepharose (Q) and CM-cellulose support (H). RNase A 
incubated with 0.5 M glucose, fructose, or ribose at 37°C for 8 days followed by 
dialysis in soluble RNase A and elution of the enzyme from immobiUzed 
preparation as described in the method section. Hyperchromicity was calculated 
taking the value of sample incubated without sugar as 100. All values are mean ± 
S.D for three experiments performed in duplicates. 
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hyperchromicity of the CM-cellulose bovind preparation was slightiy and that of 
the antibody bound preparation remarkably lower as compared to that of the 
soluble enzyme incubated with the sugars. Conformational alterations resulting 
from the exposvure to sugars is also evident from the measurement of fluorescence 
quenching determined after excitation at 280 nm and emission between 300-400 
run. Fig. 51 showed that maximvun quenching was observed in case of the soluble 
preparation while RNase A that remained bound to the antibody support during 
exposure with the sugars showed minimum quenching. As observed in experiment 
with hyperchromicity, exposure to ribose caused maximimi quenching. 
Results with various sugars also show that ribose was most active in increasing 
new fluorescence and as compared to the soluble enzyme and that bound to CM-
cellulose, RNase A immobilized on antibody support exhibited minimum new 
fluorescence (Fig. 52). 
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Fig. 51. Effect of various sugars on tyrosine fluorescence of soluble RNase A (D), 
RNase bound to antiRNase A Sepharose (B) and CM-cellulose support (0). RNase 
A incubated with 500 mM glucose, fructose, or ribose at 37°C for 8 days followed 
by dialysis in soluble RNase A and elution of the enzyme from immobilized 
preparation as described in the method section. Quenching in tyrosine 
fluorescence was calculated taking the value of sample incubated without sugar as 
100. All values are mean ± S.D for three experiments performed in duplicates. 
Fig. 52. Effect of various sugars on new fluorescence of soluble RNase A (D), 
RNase A bound to antiRNase A Sepharose (EI) and CM-celltdose support (0). 
RNase A incubated with 500 mM glucose, fructose, or ribose at 37°C for 8 days 
followed by dialysis in soluble RNase A and elution of the enzyme from 
immobihzed preparation as described in the method section. Increase in new 
fluorescence was calculated taking the value of sample incubated without sugar as 
100. All values are mean ± S.D for three experiments performed in duplicates. 
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5.0. DISCUSSION 
In an effort to evaluate simple and useful assay strategies for the screening of 
substances that interferes with glycation, two proteins HSA and RNase A were 
selected. Three sugars glucose, fructose and ribose with known differences in 
reactivity were used and a comparison was made of changes in the proteins 
induced by the sugars. The alterations studied included behavior in SDS-PAGE, 
intrinsic fluorescence, hyperchromicity and new fluorescence as well as adduct 
formation using ketoamine and borohydride-periodate assays. In case of RNase A, 
decrease in the abiHty to hydrolyze yeast RNA was also taken as a measvure of 
glycation. 
HSA is the most abundant protein in blood constituting about 40 mg/ml plasma 
(Shaklai et aJ., 1984). HSA function as a carrier of wide variety of substances 
including amino acids, metals, hormones, metaboUtes like bilirubin, hemin and 
fatty acids and many therapeutic compounds. HSA plays a protective role in vivo 
as an antioxidant (Bourdon et al., 1999). In normal individuals, nearly 10 % of the 
HSA is modified by glycation and the modification increases 2-3 folds under 
hyperglycemic condition (Guthrow et al., 1979). Glycated albvraiin is therefore 
considered a useful marker for short term monitoring (2-4 weeks) of diabetic 
patients. The level of glycated albxmiin reflects the degree of hyperglycemia in 
diabetes (Nakajou etal., 2002). 
Glycation of protein has been shown to result in protein degradation and/ or 
crosslinking (Singh etal., 2001; Rosea et al, 2005) and the observed alterations in 
the migration behavior of HSA incubated with the sugars (Fig. 10) apparently 
results from such effect. Glucose was least reactive but additional small molecular 
weight bands appeared in the gel after 8 days of incubation (Fig. lOA). 
Interestingly, samples incubated with fructose and ribose migrated as highly 
diffuse bands with the increase in incubation time and showed the presence of 
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aggregates rather than fragments (Fig. lOB). High reactivity of the Amadori and 
other intermediate generated by ribose and fructose (ref) may contribute towards 
aggregate formation. Incubation of HSA with sugars also resulted in a time-
dependent induction of carbonyl groups in the molecule which increased more 
rapidly in the samples incubated with ribose (Fig. 11). It is well recognized that 
carbonyl groups are introduced in the proteins as a consequence of glycation, and 
protein carbonyl content is considered as a reUable measure of glycation (Beal, 
2002). Similarly, new fluorophore formation, quenching of intrinsic fluorescence, 
hyperchromicity at 280 nm as well as loss of tertiary structure, as evident from CD 
measurement were most prominent in HSA incubated with ribose. The difference 
in observed rates of inactivation resulting from the incubation with various sugars 
is attributable to their relative reactivities in glycation reactions (Seidler, 2005), 
which in turn dependent upon the concentration of the respective open chain 
form at equilibrium (Kaneto, 1994). Ketoamine and periodate assays however 
were contradictory showing fructose to be least reactive among the three sugars 
(Fig. 12, 13). The failure of these colorimetric assays to detect the Amadori product 
formed by the fructose may explain the observation. The Amadori product (AP) 
formed by fructose is an aldehyde with a carbonyl at C-1 which is unable to 
cyclize and hence cannot react with redox dyes such as NBT in the fructosamine 
assay and it also does not liberate formaldehyde in periodate assay from which the 
chromophores are generated. 
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It is now well recognized that reaction of proteins with reducing sugars can cause 
marked alterations in their structure and conformation (Ahmed, 2005). The 
resulting covalent crosslinking may induce stress in the molecule, triggering the 
overall structural changes as revealed by quenching in intrinsic fluorescence, 
hyperchromicity, generation of new florescence and alterations in the CD spectra 
(Fig. 14, 15 and 16). Loss of intrinsic fluorescence is attributed to the destruction 
of the tryptophan and/or modification of the tryptophan microenvironment 
(Davies et al., 1987). With increase in time of incubation with sugars there was a 
consistent increase in the peak value of emission in range 400-500 lun that 
suggests the formation of glycation adducts and AGEs. Increase in absorbance at 
280 imi (Fig. 16) is attributed to protein luifolding and exposure of the buried 
chromophoric groups to the solvent (Traverso et al., 1997). CD spectra (Fig. 17) 
also showed alterations in the helical behaviour of HSA. The structural alterations 
suggest by an increase of beta structiure and random coil at the expense of alpha 
helix. The incubation of HSA with sugars appears to promote conformational 
changes leading to instability in the secondary structure. A comparison of intrinsic 
fluorescence with far CD in a recent study confirmed that glycated HSA lost 
tertiary structure before losing secondary structure (Mendez et al., 2005). While 
the alterations in behavior of protein reported here are common to most proteins, 
the magnitude of glycation-induced changes may vary. It was shown earUer that 
while amino groups are primary targets, the extent of glycation does not directly 
depend on the number of glycation-prone residues but on the solvent accessible 
surface area of such residue (Moulick et al., 2007). These studies however 
suggested that fructose and ribose behave very similar to glucose but react faster 
with HSA leading to more rapid modification of the protein. 
A number of natiural or synthetic compounds and drugs as AGE inhibitors have 
been proposed and identified. We have studied the protective effect of some metal 
ion chelators, antioxidants, analgesics and other drugs that have been shown to 
103 
a 
'iscusston 
interfere with glycation by restricting structural alterations, protein crosslinking 
etc. For this study fructose was selected as a model sugar because of its high 
reactivity as compared to glucose and the fact that atleast in some tissues in vivo, 
glycation with the sugar is significant tmder specific conditions (Kinoshita et al., 
1979; Tomblinson, 1985). The inhibition of crosslinking and conformational 
alterations by radical scavengers and metal ion chelators DETAPAC and EDTA 
strongly suggest the role of firee radicals in glycation. DETAPAC and EDTA are 
beheved to act by preventing metal catalyzed oxidation of sugars (Wolff and Dean, 
1988, Well-Knecht ef al., 1995). Aminoguanidine on the other hand blocks the 
formation of sugar carbonyl and ketoamine or their derivatives by competing with 
nucleophiUic groups on proteins (Thomalley, 2003). Aspirin protect proteins 
against glycation by acetylating the firee amino groups (Swamy and Abraham, 
1989) while analgesics like ibuprofen and paracetamol act by reducing the 
oxidative stress (Malik, 1996). Our experiments (Fig.l8,19) suggested that ascorbic 
acid was least effective of all the inhibitors studied in preventing structural 
changes associated with glycation. Ascorbic acid is structurally similar to sugars 
therefore it is possible that it competes with fiiictose for sites of glycation. The 
protective property of ascorbic acid is also attributed to its abihty to scavenge firee 
radicals that play an important role in glycation reactions (Malik, 1996). The exact 
mechanism of action of these compoxmds needs to be fiuther elucidated. The 
present study however indicates that these are powerful inhibitors which may act 
at multiple steps of glycation and AGE formation. This study also shows that 
fructose can be conveniently xised as a model sugar for study of glycation 
inhibitors except while using the periodate and ketoamine assays. 
There are reports of several plant products that show remarkable AGE inhibitory 
activity. These include resveratrol, a natural estrogen present in grapes (Mizutani 
et al, 2000), curcumin found in trumeric (Sajithlal et al., 1998), S-allylcysteine a 
constituent of gariic (Ahmad and Ahmed, 2006), rutin that occurs in tomatoes 
104 
2)/j 
'iscussjoa 
(Kiho et al., 2004) and polyphenolic compounds in Zea mays (Farsi et al., 2008). 
Green tea contains tannins (flavonoids) having significant antiglycation properties 
(Nakagawa et al., 2002). Dearlove et al. (2008) showed polyphenoUc substances in 
extracts of various herbs and spices inhibit fructose-mediated protein glycation. 
Several flavonoids are also known to act as antioxidants (Wu and Yen, 2005). Since 
some antioxidants also act as inhibitors of glycation (Urios et al., 2007), we studied 
the effect of some flavonoid on HSA glycation by fructose. Some bioflavonoids 
have also been shown to reduce formation of glycated hemoglobin (Manuel et al., 
1999). According to Matsuda et al. (2003), the principal structural requirement of 
flavonoid for the inhibition of AGE formation, is the presence of vicinyl 
dihydroxyl group at 3'-, 4'-, 5 and 7-position. All the flavonoids used in our study 
fulfil this requirement, although the magnitude of their inhibition on the 
glycation reaction varied remarkedly. 
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Chir finding herein showed the reduced formation of glycation adducts in the 
presence of rutin and quercetin which is comparable with the protection provided 
by DETAPAC, EDTA and aminoguanidine. However 10 fiM rutin and quercetin 
produced inhibitory effect with that of 25 mM aminoguanidine or DETAPAC, 
which is remarkable. The chelators used in the experiment were present in excess 
to ensvire TnaviTnum inhibition. Inhibition of firee radical generation derived from 
protein glycation and subsequent inhibition of protein modification is one of the 
mechanisms of prevention of glycation (Farrar etaJ., 2007). The results suggest the 
usefulness of the assays in screening of the inhibitors of glycation and potential of 
some flavonoids in reducing the glycation-induced protein damage. 
The data however suggest that inhibition of the formation of fluorescent adducts 
and AGEs presiunably ocoirs by trapping of the ROS and carbonyl intermediates. 
Another parameter used for the study of protein glycation is the formation of 
protein crosslinks. Restriction of the crosslink formation by flavonoids suggests 
that their inhibitory activity is not only due to their antioxidant properties but 
also to some additional mechanism. In a recent study polyphenol rich extracts 
from the plant Ilex paraguariensis have been shown to inhibit the formation of 
AGEs (Lxmceford and GugUucci, 2005). In addition, green tea extract containing 
polyphenolic compounds have also shown to delay diabetic complications (Vincen 
and Zhang, 2005). 
Our data suggest that micromolar concentration of flavonoids effectively reduce 
the sugar-induced protein damage. Consumption of the plant products in diet may 
therefore contribute to the restriction in protein glycation. Further 
characterization of flavonoid metabolites and metabolite structure-function 
relationship may lead to a better understanding of the role of these compounds in 
delaying progression of complications related to hyperglycemia. The study also 
suggests that fructose-induced glycation of HSA can be convenientiy followed by 
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the meastirement of hyperchromicity, tryptophan fluorescence, new fluorescence 
as well as electrophoretic behavior of protein in the presence of SDS. 
Earlier studies have shown that RNase A incubated with sugars undergoes 
structural modification and loss in catalytic activity (Khalifah et al., 1996). As 
shown in Fig. 24, glucose, fructose or ribose caxise marked inhibition of RNase A 
activity at 37° C and the loss of catalytic activity was most rapid in the presence of 
ribose. Incubation with glucose, fructose or ribose resulted in loss of 35, 62 and 84 
percent activity respectively in eight days. The difference in observed rates of 
inactivation resulting from the incubation with various sugars as discussed earUer 
is attributable to relative reactivities of the sugars in glycation reactions (Seidler, 
2005). The remarkably high reactivity of ribose towards RNase A may also be 
related to the structural similarity of the sugar with the enzyme substrate. 
Pancreatic RNase A is an extensively studied and highly thermostable enzyme 
(Raines, 1998). RNase A undergoes remarkable alteration in structure and catalytic 
activity when incubated with glucose and other reducing sugars as discussed 
earher. Lysine is a constituent of the active site of RNase A (Heinrickson, 1966), 
which is apparently highly reactive towards sugars and incubation with sugars 
residted in a rapid inactivation of the enzyme. Since ribose is closely related to the 
enzymatic substrate of RNase and Lys-41 of the active site most easily form 
Amadori products (Watkins et al., 1985) and AGEs (Brock et al., 2003). Fig. 36 A 
shows that the catalytic activity of the enzyme is barely affected by incubation in 
the absence of sugars at 60°C for two days while the activity loss was remarkable 
in presence of the sugars especially ribose under the same conditions. This 
facihtated the assay of glycation at 60°C at which reactivity of sugar is very high 
which reduced the assay duration to two days. Most of the glycation assays used 
currently require weeks and even months. In an earlier study Matsuura et al., ( 
2002) have used BSA at 60°C to increase the rate of glycation however albumin is 
known to undergo tmfolding at such temperature (Takedo etal, 1993). 
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The loss in activity of RNase A resvilting from the incubation witii various sugars 
was comparable when either soluble or immobilized RNase A was used. This 
suggested that immobilization does not markedly alter the reactivity of sugars 
towards enzyme. It is interesting that RNase incubated in absence of sugars for 
two days at 60°C exhibited only minor alterations in hyperchromicity, quenching 
of intrinsic fluorescence and CD spectral behavior, suggesting the retention of 
three dimensional structure of enzyme (Fig.37,38, 39 and 40). While it is true that 
ribose is not the principle sugar responsible for in vivo glycation reactions, 
structural alterations induced by ribose in proteins are similar to those caused by 
glucose. This include the cross reactivity of AGEs generated by the sugar with anti 
AGE antibodies raised against protein Glycated using glucose (Nagai and Horiuchi, 
2003). In addition, ADP-ribose may actually cause glycation of proteins in vivo, 
although to a smaller degree (Cerventes-Lauren et al., 1996). We therefore felt 
that a combination of RNase as model protein and ribose as model sugar provides a 
remarkable advantage in cutting down the assay duration and facilitates the rapid 
screening of inhibitors of glycation. 
The comparable sensitivity of immobilized RNase A with that of its soluble 
covmterpart towards glycation induced enzyme inactivation points out to the 
possibiHty of using the later with added advantage for screening of the anti 
glycation principles from natural source. Immobilized RNase A, in addition to 
being more stable (Younus et al., 2001), offers the possibility of its rapid removal 
from the reaction mixture and hence elimination of components of the crude 
extracts that may interfere with the enzyme assay. As shown in Fig. 42, an 
excellent agreement between protections offered by DETAPAC, EDTA, 
aminoguanidine, paracetamol and ascorbic acid was observed when either soluble 
or immobilized RNase A was used. 
Similarly, among the plant extracts that exhibited significant protective effects 
against ribose induced inactivation of RNase A, excellent agreement was observed 
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in case of ginger, garlic and bitter gourd extracts both with soluble or immobilized 
enzyme. The extracts like those of green tea, grapes and tomato however appeared 
more protective when immobiUzed RNase A was used as discussed earUer, due to 
interference in the assay by components of the coloured extracts (Fig. 43). Since 
the concentration of ribose used in the assay is remarkably high, interference by 
the anuno group modifying molectdes present in the extract may not be significant 
tmless they are highly reactive. 
These results suggest the usefulness of RNase-ribose assay for the rapid screening 
of extracts for inhibitors of glycation. Since only measurement of catalytic activity 
of RNase A are required, a simple spectrophotometer is adequate for the analysis. 
Also use of immobilized RNase A provides additional advantage of high storage 
stabihty (Yoimvis et al., 2001) and possibility of distingiiishing between early and 
posts Amadori inhibitors of glycation. For the study of such inhibitors, rapid 
removal of the glycating sugar after initial reaction with protein is reqviired. This 
is normally accomplished by dilution or dialysis (Matsuvira et al., 2002). 
Immobihzed RNase A on the other hand can be readily separated from the 
reaction mixture instantaneously by centrifugation and/ or filtration and freed of 
the sugar by washing. The immobilized enzyme will however not be reusable 
since part of the activity will be irreversibly lost during each assay. 
A number of enzymes have been shown to undergo glycation induced loss in 
catalytic activity both in vivo and in vitro. Cabellero et al. (1998) and Bousova et 
al (2005) suggested that the loss of catalytic activity of 6-aminolevuUnic acid 
dehydratase and aspartate aminotransferase may be vise as a measure of glycation. 
RNase A offers additional advantage being remarkably more stable and faciUtating 
reaction at high temperature and thus cutting down the assay duration. Since the 
assay involves measurement of protection of RNase A activity, we believe it will 
measure only those substances that restrict the glycation reaction. Natural 
Inhibitor of RNase A present in the extract may contribute additionally towards 
109 
a 
'iscussiaa 
the inhibition but can be taken care of by using an appropriate control in which 
enzyme may be preincubated with extract for short durations. Similarly possible 
by activators of the enzyme and/or RNase A present in the extract may corrected 
by miming parallel appropriate controls. 
Result shown in section 4.4 shows that antiRNase A antibody support protect the 
bovmd enzyme against inactivation and other alterations induced on incubation 
with reducing sugars. As shown in Fig. 48 the remaining activity of RNase A 
immobiHzed on CM- cellulose and incubated for eight days with sugars was only 
slightiy higher than that of soluble enzyme incubated vuider the conditions. 
RNase A bound to the antiRNase A antibody support however retained markedly 
higher activity as compared to the soluble and CM-celltdose-bound enzyme. 
Apparentiy immobilization per se is not responsible for the observed protection 
provided by the antibody support, since CM- cellulose bound enzyme was only 
moderately protected (Fig. 48). It is interesting to note that RNase A is expected to 
bind to CM cellulose via side chain amino groups which are potential target of 
glycation reaction (Ganea and Harding, 2005), yet the observed protection against 
sugars was small. RNase A immobilized on the antibody support was however 
clearly more resistant to the sugar-induced alterations and also showed minimum 
alteration in the electrophoretic behavior (Fig. 49). 
Spectroscopic studies of the soluble RNase A, and that incubated ^ t h the sugars 
while remaining boxmd to the antibody Sepharose further revealed the protective 
role of the antibodies (Fig. 50, 51 and 52). Considerable evidence suggests that 
binding of antienzyme antibodies to enzymes improves their resistance to 
inactivation induced by heat and other agents (Saleemuddin, 1999). Our more 
recent studies have also shown that inactivation of Cu,Zn-SOD by sugars (Jabeen 
and Saleemuddin, 2006a), glyoxal (Jabeen et al, 2007) and methylglyoxal Qabeen 
et al., 2006b) can be restricted by complexing the enzyme with specific 
antibodies. In addition binding with antibody/antibody fragment resulted in 
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restriction of enzyme aggregation as revealed by SELDI-TOF spectroscopy. Since 
both monomeric Fab and Fab2 were protective, binding per se rather than 
crosslinking induced by the bifiinctional antibodies fragment appears to be 
responsible for the observed protection Qabeen et al., 2007). The observation that 
enzyme bovmd to the antibody support is also resistant to glycation support this 
argument, since crosslinking of the antibody is less likely on the antibody support. 
Binding of antibodies to pTOteia anngen results in marked lowering of the free 
energy and stabilization of the protein antigens because of the high association 
constant. Hydrogen exchange rate investigation on lysozyme and cytochrome c 
anude group suggested that in the complex, the exchange rates were remarkably 
low not only at the point of contact between the antigen and the antibody but also 
in the regions far removed from the epitope recognized by the antibody (Rizzo et 
al., 1992; Williams et al., 1996). Several enzymes complexed with 
monoclonal/polyclonal antibodies exhibit enhanced stabihty against various forms 
of inactivation (Saleemuddin, 1999). Our earUer studies have shown that 
antibodies raised against the labile region of RNase were more protective than 
those recognizing the N-terminal peptide (Yovmus et al., 2001). The labile region-
specific antibodies also improved the thermal stabihty of a mutant RNase in which 
the labile region contained an altered cysteine (Younus et al., 2002). Studies with 
anti- lysozyme antibodies however suggest that binding of the monoclonal 
antibody raised against the native enzyme improves the thermal stability of the 
enzyme even when it do not recognize epitopes located close to the mutation site. 
Thus D67H mutation of the human lysozyme related to systemic amylodosis 
undergoes partial unfolding and aggregation with a melting temperature 10° C 
lower than that of the native enzyme (Canet et al., 2002). Binding of c-Ab-HUL6 
increased the melting temperature of the enzyme by 15°C, although the residue 
whose mutation leads to the destabilization and aggregation did not belong to the 
epitope and does not make any contact with the antibody (Dumoulin, etal, 2003). 
I l l 
a discussion 
It may not be therefore essential to identify the specific epitope(s) of the target 
protein for raising protective antibodies, although such a selection may improve 
the effectiveness of the antibody. Further studies are however needed to establish 
that nature of protection against glycation is also similar. 
Several advantages of immobilization of enzyme on antibody supports have been 
identified (Saleemuddin, 1999) and work described in this paper suggests enzjmies 
immobihzed thus may also be resistant to glycation induced alterations. A nvunber 
of enzymes that catalyze transformations of reducing sugars or those that 
generates reducing sugars are employed in immobilized state in biosensors and 
reactors for continuous operation. Such enzymes may be exposed to reducing 
sugars continuously over long dviration. Binding to antibody support may help 
extend the life of such reactors and sensors. 
The mechanism by which antibodies protect enzyme against glycation needs 
further study. Binding of the antibodies may increase the conformational rigidity 
of the protein antigen and restrict xmfolding. The antibodies may therefore 
decrease the possibility of sugar reacting with additional susceptible groups of the 
enzyme Qabeen et al., 2007). Some chaperones may protect the enzyme against 
glycation using similar mechanism (Yan and Harding, 2006). The observation that 
RNase A exposed to the sugars while remaining bound to the antibody support 
imdergo fewer structural alterations supports this view. 
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abstract 
A procedure for the rapid screening of inhibitors of glycalion reaction, based on their ability to protect RNase against sugar induced 
inactivation of llie enzyme is described. Glycation is implicated in variety of disorders including diabetes, atherosclerosis various micropathies yet 
s a slow process both in vivo and in vitro. In order to speed up glycation, the reaction was carried out at 60 °C using a thennostable protein RNase 
.ind ribose, a sugar that is known to react rapidly than glucose in the glycalion reaction. It was observed that incubation of RNase with ribose at 
<i() ''C in rapid inactivation of the enzyine with a parallel decrease in tyrosine fluorescence, enhancement in new fluorescence and hyperchromicity 
II) the UV-rcgion. No such alterations in the enzyme activity were observed when the incubation was carried out in absence of the sugar. 
I ompounds and drugs that are known to act as inhibitors of glycalion reaction restricted the ribose-induccd inactivation of RNase. RNase 
:niinobili/ed on CNBr-activatcd Sepharose was also sensitive to exposure to ribose and appeared a better system to screen inhibitors of glycation 
from natural sources that contain substances that interfere with the assay of enzyme as well as in the study of post Amadori inhibitors of glycation. 
' ' 2007 Elsevier B.V. All rights reserved. 
\^•\^vor(ls: Olvcation inhibitoi-s; RNase; Maillard rciction; Ribose 
I. Introduction 
During Maillard reaction reducing sugars react with amino 
groups of biomolecules including proteins, lipids, nucleic acids 
10 fonn Schiffbase which in turn undergoes transformation to a 
\ariety of advanced glycation end products (AGEs) [1,2]. The 
Ml vivo significance of Maillard reaction was first recognized 
with the detection of elevated levels of hemoglobin in the 
diabetic blood [3]. Subsequent evidence suggested that the AGE 
may play an important role in the etiology of variety of diabetic 
complications |4 | and aging (5,6|. AGEs have also been im-
Al'hri'viiiliniis: ACih, advanced Cilycation end products; DHIAI'AC. 
iliethylenetrianimepewa acetic acid; lUVlA. ethylcnediaminetetraacetic acid; 
\<i. aminoguanidine; RNA. ribonucleic acid; I'ACil.. polyacrylaniide gel 
.-ifctrophoresis; C'NHr. cynogcn bromide; KNase A. ribonuclease A; SI)S. 
'iidiuiu dodecyl siilphate. 
• CoiTespondini; author. Depaninent of Hiocheniislry. I'aculry of Life 
Sciences. Aligarh Muslim IJniversify. Alij;arh-202(K)2, India. I'el.: +91 571 
•"(M)^4I. tax: -"ll 571 272177fv 
l:-inail miclrcss nis.\lecnin(l(lMi47{V(,i;iTiail.con) (M. Saleemuddin) 
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plicated in a variety of disorders including inflammation [7], 
atherosclerosis [8], neurodegenerative disorders [9] and cancer 
[10]. Glycated protein may lose biological activity, turn toxic, 
develop new antigenic determinants and damage cell in a va-
riety of ways after uptake mediated by specific receptors present 
on the surface of several cells [11,12]. 
Several lines of evidence suggest that agents that restrict 
AGE formation result in reduction of various diabetic com-
plications including retinopathy [13,14] and can be considered 
as diabetic complication drugs. While several other strategies 
also appear promising [15-17], current emphasis is on the 
substances that act inhibitors of AGE formation. Among the 
compounds evaluated as AGE inhibitors, aminoguanidine (AG) 
[18], aspirin [19], vitamin B^ [20] taurine [21] and quercitin 
[22] are important. Among these AG is in late stages of clinical 
trials, yet the effective dose of aminoguanidine is quite high 
with accompanying risks of side effects. In search of alternative 
drugs, screening of natural sources for potential glycation in-
hibitors has also been undertaken [22]. The standard proce-
dures of assay of glycation require sophisticated equipment 
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12.1), expensive reagents like antibodies [24] and are time con-
suming requiring days and weeks because of the slow reaction 
of sugars witli protein. Some attempts have been made to cut 
down assays duration by replacing glucose with reactive sugars 
like ribose [25] and by increasing the incubation temperature 
[26j. Matsuura et al. [26] described an assay in which the rate of 
reaction of glucose with BSA was accelerated by performing the 
incubation al 60 "C. AGE formation was detected by measuring 
quenching of intrinsic fluorescence and generation of the new 
fluorophore (Ex. 370. Em. 440 nm). While the authors claimed 
that incubation did not alter the native conformation of the 
protein, earlier studies suggest greater susceptibility of the 
BSA denaluration induced at such temperature [27]. A simple 
strategy for the screening of giycation inhibitors based on their 
ability to protect the catalytic activity of an enzyme sensitive 
to giycation is described in the manuscript. Bovine pancreatic 
ribonuclease (RNase) has been selected in view of its well 
known thenno stability [28] and the giycation reaction was 
carried out using a highly reactive sugar ribose at 60 °C [29]. 
The problem of interference by in the assay by substances 
present in the plant extract could be better addressed using an 
immobilized preparation of RNase. 
2. Materials and methods 
2.1. Materials 
Bovine pancreatic RNase A, DETAPAC, aminoguanidine, 
yeast RNA, cynogen bromide were purchased from Sigma 
Chemical Co. (St. Louis, MO, USA). Other chemicals and 
reagents for electrophoresis, glucose, fructose, ribose, lantha-
num chloride and Sepharose 43 were obtained from SRL 
Chemicals (Bombay, India). All other chemicals and reagents 
were of analytical grade. 
2.2. Glycalum reaction 
tion with the sugar and extracts prior to the enzyme activity 
measurements. 
2.3. Measurements of RNase activity 
RNase activity was determined spectrophotometrically using 
yeast RNA as substrate. The standard reaction mixture in a total 
volume of 2.5 ml contained 2 mg of RNA and appropriate 
amount of RNase A in 0.1 M sodium acetate buffer, pH 5.0. The 
reaction was arrested after 10 min incubation at 37 °C by using 
stopping reagent (22 M lanthanum chloride in I M perchloric 
acid), the reaction was left on ice for 10 min and the precipitate 
removed by centrifiigation. Subsequently 0.2 ml of the super-
natant was diluted with distilled water and the absorption of acid 
soluble ribonucleotides measured at 260 nm [31]. 
2.4. Spectroscopic analysis 
The UV absorption measurements of RNase incubated with-
out sugar (control) and that incubated with glucose, fructose 
and ribose were obtained by measuring the absorption between 
200 and 350 nm in a Shimadzu spectrophotometer using a cuvette 
of 1.0 cm path length. Similarly, control and RNase incubated 
with sugars were studied by measuring intrinsic fluorescence 
at 25±0.2 °C in a Hitachi F 2000 spectrofluorimeter (Tokyo, 
Japan). The samples were excited at 285 nm and emission range 
was taken at 310-400 nm. New fluorescence measurements 
were also made at 370 nm and an emission range of 400 500 nm. 
2.5. Electmphoresis 
The electrophoretic behavior of control RNase samples and 
those treated with the sugars was analyzed by SDS-PAGE [32]. 
A resolving gel of 10% (w/v) acrylamide in tris HCI buffer, pH 
8.8 with 0.1% SDS was employed. Silver staining of the gels 
was perfonned for the visualization of protein bands [33]. 
RNase (I mg/mi) was incubated with 0.5 M glucose, fruc-
tose or ribose in 0.02 M phosphate buffer pH 7.2 at 60 °C for a 
period of I. 2 and 4 days under sterile conditions. The incu-
bation was carried out under sterile condition but also con-
tamed 5 nM gentamycin as an additional precaution. Where 
indicated RNase was incubated with the chemical inhibitors 
(25 mM) or plant extracts in the presence of 0.5 M ribose. 
Control samples were incubated under similar conditions but 
without ribose and inhibitors. Similarly RNase was incubated 
with some plant extracts along with 0.5 M ribose and incubated 
for 2 days under similar conditions. The plant extracts were 
prepared by homogenizing garlic, ginger, grapes, bitter gourd, 
turmeric and tomato in 0.02 M phosphate buffer pH 7.2 
followed by centrifiigiition and 25 ^^\ of the supernatant was 
added to the reaction mixture. Green tea extract was prepared 
by stirring I g of green tea with 20 ml of 50% (v/v) ethanol 
for 3 h. The mixture was centrifuged at 1500 xg for 15 min 
and the supematant was u.sed as green tea extract [30]. All the 
extracts were adjusted to assay pH. While using immobilized 
RNase the preparation was washed thoroughly after incuba-
2.6. Circular dichroism 
All the Circular dichroism (CD) measurements were carried 
out at 25 °C on a Jasco spectropolarimeter Model J-720 using a 
SEK.0N1C XY Plotter (Model SPI-430A), with a thermostati-
cally controlled cell holder attached to a NESLAB water bath 
Model RTE 110 with an accuracy of ±0.10 °C. The instrument 
was equipped with a microcomputer and recalibrated with (+)-
10-camphersuIfonic acid. The spectrum was recorded with a 
scan speed of 20 nm/min and with a respon.se time of 20 nm/min. 
Each spectrum was recorded as an average of two scans. Far-UV 
CD spectra and near-UV CD spectra were taken at a protein 
concentration of 20 fiM with a I and 10 mm path length cells, 
respectively. CD spectra were recorded in the wavelength ranges 
of 190 250 nm for far-UVand 250 310 nm for near-UV. 
2.7. Inimohilization of RNase on CNBr activated Sepharose 
Immobilization of RNase was carried out as described earlier 
[34]. Sepharose 4B washed thoroughly with distilled water in a 
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sintered glass flinnel, sucked dry and suspended in I ml of 
:.0 M NaiCOv Two hundred mg of CNBr in 0.2 ml of ace-
u)nitrile added to I g of Sepharose and the suspension was 
placed at 4 °C for 10 min with continuous stirring. The whole 
mass then washed thoroughly with 0.1 M bicarbonate buffer 
pH 8.5 and water. RNase (10 mg) was added to the activated 
Sepharose in 0.1 M sodium bicarbonate buffer pH 8.5 under 
>lirring for 24 h at 4 °C. Amounts of the enzyme immobilized 
were determined by subtracting from the amount added those of 
ilie supernatant and washing by activity measurement. Under 
ijie conditions used 8.3 mg of RNase/gram of Sepharose was 
coupled to the matrix. 
y. Results 
V /. Effect of incubation with sugars on RNase activity 
As has been reported earlier [28] bovine pancreatic RNase 
ivas themiostable and retained nearly complete enzyme activity 
;il'ter incubation at 60 °C for two days (Fig. I A). Extension of 
ihe duration of incubation to four days resulted only in loss of 
;ibout 10% RNase activity. Incubation of RNase with reducing 
sugars at 60 °C however resulted in rapid inactivation of the 
onzyme. Among the sugars investigated, ribose was most active 
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Fig. 2. Effect of sugars on the spectral properties of RNase. RNase (1 mg/ml) 
incubated with 0.5 M gluccse, fhictose, or ribose at W) "C" for 2 days followed by 
dialysis to remove excess sugar. Solutions were diluted to a concentration of 
150 |ig/ml for analysis of new fluorescence (A), tyrosine fluorescence (Bj. and 
hyperchronucity (C). 
causing the loss of about 80% RNase activity in two days and 
the enzyme inactivation increased to 90% after four days of 
incubation. Glucose and fructose also inactivated RNase but to a 
smaller extent and a two day incubation at 60 °C resulted in 20 
and 60% loss of the enzyme activity respectively. RNase 
coupled to the CNBr-activated Sepharose was also su.sceptible 
to inhibition by reducing .sugars at 60 °C and the pattem of 
inhibition resulting from the incubation with sugars with im-
mobilized RNase was comparable with that observed with the 
.soluble enzyme. 
3.2. Effect of incubation with sugars at 60 °C in the .spectral 
properties of RNase 
It is now well recognized that reaction of reducing sugars 
with protein can cause marked alterations in protein conforma-
tion [35.36]. Incubation with reducing sugars at 60 °C resulted 
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in modification in soluble RNase as evident from the obsei-ved 
alteration in intrinsic fluorescence, new fluorescence and ab-
sotbance at 280 nm (f"ig. 2). As shown in the figure RNase 
incubated with the reducing sugars revealed a marked increase 
in absorbance at 280 nm and new fluorescence while the 
quenching was observed in the intrinsic tyrosine fluorescence. 
Ribose was most reactive in causing alterations followed by 
fructose and glucose. Several investigators have shown that 
reaction of sugars and dialdehydes with protein can also lead to 
the formation of groups that show strong emission between 400 
and 500 nm when excited at a wavelength of 370 nm [37,38]. 
Incubation of soluble RNase with reducing sugars also resulted 
in marked decrease in intrinsic fluorescence and increase in 
absorbance at 280 nm and the magnitude of the alterations was 
maximum with ribose and least with glucose. Quenching in 
the tyrosine fluorescence is attributed to the exposure of the 
phenolic groups to a less hydrophobic environment [39]. Sim-
ilarly, increase in absorbance at 280 nm is attributed to protein 
unfolding and exposure of the chromophoric groups [40]. A 
comparison of the alteration in RNase was summarized in 
Fig. 3. As evident, among the parameters studied, alterations in 
enzyme activity were most prominent. 
Fig. 4 depicts the far UV-CD spectra of control and ribose 
treated RNase incubated for 1,2 and 4 days at 60 °C between 
205 and 250 nm. As can be seen fi-om the figure no remarkable 
change in the spectnim of RNase incubated in the absence of 
sugar was observed while inclusion of ribose in the reaction 
mixture resulted in a time dependent alterations suggestive of 
marked loss of secondary structure. Seilder [41] suggested that 
changes in secondary structure could lead to localized com-
paction of the protein. 
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Fig. 4. Circular dichruic spectra of RNa.se incubated in the absence (A) or 
presence (B) ofribo.se for I, 2 and 4 days at 60 °C in far UV region. Solutions 
were diluted to a concentration of 230 (jg/nil for the .spectral analysis. 
i.i. SDS-PAGE of RNase incubated with sugars 
RNase exposed to the various reducing sugars at 60 °C 
was subjected to SDS-PAGE in presence of the thiol reductant 
(^-mercaptoethanol. Fig. 4 showed that incubation of RNase 
with the reducing sugars with the enzyme resulted in marked 
broadening of the bands and/or decrease in electrophoretic 
mobility suggesting crosslinking. Elbe et al. [42] have shown 
earlier that comparable alterations occur in RNase incubated 
with glucose at moderate temperature but up to 14 days. The 
alteration in electrophoretic behavior was most prominent in 
RNase incubated with ribose followed by those with fructose 
and glucose. 
3.4. Effect of some glycation inhibitors 
The protective effect of some metal ion chelators, anti-
oxidants, analgesics and other drugs that have been shown to 
interfere with glycation, on the activity of some soluble and 
immobilized RNase incubated with ribose at 60 °C was al-
so investigated. DETAPAC was most effective in protecting 
the enzyme activity, followed by aminoguanidine, EDTA and 
pencillamine, aspirin and paracetamol. Ascorbic acid and ibu-
profen were less inhibitory. As evident from Fig. 5, a good 
correlation was observed between the extents of protection 
provided by several compounds when either soluble or im-
mobilized RNase was used. An excellent agreement in the 
protection offered by DETAPAC, EDTA, aminoguanidine, 
paracetamol and ascorbic acid was observed when either sol-
uble or immobilized RNase was used. In case of aspirin and 
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B D 
. iu 5 SDS-I 'AGK analysis of the eflecl of incubation with various sugars 
iiir two days at 60 ''C on RNast. RNase was incubated in the absence of sugar 
(Lane AI or presence of 0.5 M glucose (Lane B). 0.5 M fructose (Lane C) or 
II 5 M nbose (Lane D) 
ibiiprofen however the protection appeared more marked wheti 
ihe immobilized enzyme was used. The difference may be at-
iributed lo interference by the drugs in the determination of 
oluble RNase activity. Since the activity of immobilized RNase 
was measured after centriftigation and washing of the immobi-
lized enzyme, the interference by the drags in the assay is 
apparently eliminated. Aspirin is known to act by acetylation of 
free amino groups of proteins [43] and hence may contribute 
;idditional!y towards the inhibition of RNase. While similar 
iiction can be envisaged in case of the immobilized enzyme, it 
IS not unlikely that some of the crucial side chain amino groups 
ire less accessible in case of the immobilized RNase. Para-
cetamol is however, not known to lead to such modification. 
Ability of some plant-derived extracts to protect RNase 
.igainst inactivation induced by ribose was also measured at 
i>0 °C. As shown in Fig. 6, green tea extract, ginger, garlic, 
grape, tomato and bitter gourd were markedly protective against 
the inactivation of both soluble and immobilized RNase. The 
' / V' V~ <///^^ 
y^ 
\ ig. ii. Kl'fctl of various compounds at a concentration of 25 mM on the activity 
ol RNase incubated with 0.5 M ribose at 60 °C for 2 days. Activity of RNa.se 
iicuhatcd in absence of ribose was taken as lOOI'o for calculation of peiccnt 
.'ti\ uy in treated siiniples 
I'ig. 7. Lffect of some plant evtraets on activity of RNase treated with 0.5 M 
ribose at 60 "C for 2 days Activity of RNase incubated in absence of ribose was 
taken as 100% for calculation of percent activity in various .samples. 
observed protection by ginger and bitter gourd extract was 
comparable when either soluble or immobilized RNase was 
employed. There was however observed variation in the mag-
nitude of protection in case of the intensely colored extracts 
derived from tomato, grapes and turmeric and the extent of 
protection appeared more marked in case of the soluble enzyme. 
Thus, while incubation of soluble RNase with green tea extract 
resulted in the retention of 34% of control activity that observed 
with immobilized enzyme was 70%. Similariy, the observed 
retention in of the RNase activity incubated with the extracts of 
grape, tomato and turmeric extracts were respectively 33%, 
3l?/o and 42% while using soluble enzyme and 59%, 60%, and 
64% when immobilized enzyme preparation was used (Fig. 1). 
4. Discussion 
Pancreatic RNase is an extensively stxidied thermostable 
enzyme [28]. RNa.se undergoes remarkable alteration in struc-
ture and catalytic activity when incubated with glucose and 
other reducing sugars [44]. Lysine is a constituent of the active 
site of RNase [45], which is apparently highly reactive towards 
sugars resulting in a rapid inactivation of the enzyme. Since 
ribose is closely related to the enzymatic .substrate of RNase and 
Lys-41 of the active site most easily form Amadori products 
[44]. Fig. I shows that the catalytic activity of the enzyme is 
barely affected on incubation in the absence of sugars at 60 °C 
for two days, the activity loss was remarkable on incubation 
with the sugars under the same conditions, with ribose being 
mo.st reactive. The high reactivity of ribose in glycation reaction 
has been ascribed to the stability of the open chain for the sugar 
[46]. The loss in activity re.sulting from the incubation with 
various sugars was comparable when soluble or immobilized 
RNase was used. This suggested that immobilization does not 
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markedly alter the reactivity of enzyme towards sugars. It is 
mteresting that RNase incubated in absence of sugars for two 
days at 60 °C exhibited only minor alterations in hyperchro-
micity and quenching of intrinsic fluorescence, CD spectral 
behavior suggesting the retention of three dimensional struc-
ture of enzyme (Fig. 2). While it is true that ribose is not 
the principle sugar responsible for in vivo glycation reactions, 
structural alterations induced by ribose in proteins are similar to 
those caused by glucose including the recognition of AGEs by 
anti-AGE antibodies [47]. In addition, ribose in fomi of ADP-
ribose may actually cause glycation of proteins in vivo [48], We 
therefore felt that use of RNase as model protein and ribose as 
model sugar provide remarkable advantage. 
The comparable sensitivity of immobilized RNase with that 
of its soluble counterpart towards glycation induced enzyme 
inactivalion points out to the possibility of using the later for 
screening of the antiglycation principles from natural source. 
Immobilized RNase in addition to being more stable [34] 
offers the possibility of its rapid removal from the reaction 
mi.xture and hence elimination of component of the extract that 
may interfere with the enzyme assay. As shown in Fig. 5, an 
excellent agreement between protections offered by DETAPAC, 
EDTA, aminoguanidine, paracetamol and ascorbic acid was 
observed when either soluble or immobilized RNase was used. 
Aspirin and ibuprofen however appeared more protective when 
immobilized RNase was used. 
DETAPAC and EDTA are believed to act by preventing 
metal catalyzed oxidation of sugars [49]. Aminoguanidine on 
the other hand blocks sugar carbonyl and ketaniine or their 
derivatives [50]. Aspirin protects the amino groups by acet-
ylation [43.51] while analgesics like ibuprofen and paracetamol 
act by reducing the oxidative stress [52]. The protective 
property of ascoibic acid is attributed to its ability to scavenge 
free radicals that lay an important role in glycation reactions 
[53]. Thus, the protection from glycation induced inactivation 
by compounds with remarkable difference in their mechanism 
of action could be detected by the assay system. 
Similarly, among the plant extracts that exhibited significant 
protection effects against ribose induced inactivation of RNase, 
excellent agreement was observed in case of ginger, gariic and 
bitter gourd extracts when soluble or immobilized enzyme was 
used. The extracts like green tea, grapes and tomato extracts 
however appeared more protective when immobilized RNase 
was used as discussed earlier. Since the concentration of ribose 
used in the as.say is remarkably high, interference by the mol-
ecules present in the extract, that modify amino groups of 
enzyme is not very high unless they are highly reactive. 
There are reports of several natural products in plants with 
AGE inhibitory effect. These include resveratrol, a natural estro-
gen in grapes [54], curcumin in tumieric [55), S-allylcysteine in 
gariic [56] and rutin in tomato fraction [57).Green tea contain 
tannins (flavonoids) having antiglycation properties [58J. This 
clearly makes a strong c<i.se for the screening of plants for potential 
inhibitors of glycation. 
Immobilized RNa.se may be more useful for screening of 
inhibitors that act on post Amadori reactions [26]. For the study 
of such inhibitors, rapid removal of the glycating sugar afler 
initial reaction with protein is required. This is normally ac-
complished by dilution or dialysis. Immobilized RNase on the 
other hand can be readily separated from the reaction mixture 
instantaneously by centriftigation and freed of the sugar by 
washing. Also the immobilized preparation may offer the ad-
vantage of additional storage stability [34]. 
A number of enzymes have been shown to undergo glycation 
induced loss in catalytic activity both in vivo and in vitro 
Cabellero et al. [59] and Bonsova et al. [60] suggested mea-
surement of loss of enzyme activity of 6-aminolevulinic acid 
dehydratase and aspartate aminotransferase as a measure of 
glycation. In our opinion RNase offers additional advantage 
being remarkably stable and facilitating reaction at high tem-
perature and thus cutting down the assay duration. Since the 
assay involves measurement of protection of RNase activity, we 
believe it will measure only those substances that restrict the 
glycation reaction. Natural Inhibitor of RNase present in the 
extract may contribute additionally towards the inhibition but 
can be taken care of by using an appropriate control. To con-
clude we believe that the assay described can be useful in the 
rapid detection of inhibitors of glycation, including those that 
inhibit post Amadori reactions from nauiral sources. 
5. Description of the method and its applications 
Here we described a simple strategy for the screening of 
various glycation inhibitors. Immobilized and soluble RNase 
was incubated with sugar along with inhibitors at desired 
conditions. Af^ er completion of incubation the immobilized 
preparation was washed thoroughly and activity measurement 
of RNase was perfonned. The problem of interfering substances 
present in the extract could be better addressed using 
immobilized preparation. In conclusion, the in vitro model 
described can be used to study and measure the formation of 
AGE in RNase and might help in determining the effect of 
various AGE inhibitors. Furthermore in this technique we 
removed all the possible substances that might interfere in 
the assay of RNase so that it helps in the accurate measure-
ment without involving expensive reagents and sophiscated 
equipments. 
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